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The dopamine transporter (DAT) is a plasma membrane-bound protein, 
localized on peri-synaptic terminals of dopaminergic (DA) neurons. DAT is 
responsible for terminating DA signaling by rapid removal of the transmitter from 
the synaptic cleft region.  DA signaling relies on a critical balance between 
release and removal of the neurotransmitter within synaptic clefts. Recycling of 
DAT between intracellular endosomal compartments and the plasma membrane 
regulates DAT function.  This dynamic trafficking occurs in both a constitutive 
and regulated manner to increase or decrease the number of transporters on the 
cell surface available for transmitter reuptake.  Therapeutic drugs and/or drugs of 
abuse, including psychostimulants and ethanol, cause maladaptive changes in 
DA signaling in mesolimbic areas of the brain, leading to addictive behaviors.  
DAT is the primary site of action for psychostimulants such as, cocaine, 
methylphenidate, and amphetamine.  These drugs can alter the function and/or 
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regulation of the transporter.  Ethanol, one of the most widely abused drugs in 
society, is known to activate DA pathways in reward and reinforcement areas of 
the brain.  However, the effect of ethanol on DAT function and regulation is less 
clear.  The studies presented here explore the action of ethanol on DAT function 
in mammalian cell systems, and the subcellular trafficking mechanisms that 
regulate the transporter.   To delineate mechanisms of ethanol action on DAT, 
several lines of HEK-293 cells stably expressing DAT or ethanol-insensitive DAT 
mutants were generated. Short-term ethanol exposure was found to potentiate 
DAT function, and ethanol sensitivity is mediated by specific amino acids in the 
first intracellular loop.  This increase in function was accompanied by an 
enhancement of DAT expressed on the cell surface.  The changes in DAT 
localization and the absence of consensus phosphorylation sites in the ethanol 
sensitive regions of the transporter, led to the hypothesis that ethanol modulates 
DAT uptake by altering the dynamic trafficking of the transporter. In the present 
studies, we found ethanol directly regulates DAT function by altering specific step 
of the endosomal recycling pathway.  Further analysis of the ethanol-sensitive 
first intracellular loop revealed this region might also play a role in conformational 
changes required for substrate binding.  The findings presented in these studies 
describe a novel molecular mechanism of ethanol action on DAT, and provide a 
framework to further understand the action of ethanol on synaptic dopamine 
regulation.   
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CHAPTER ONE:  INTRODUCTION 
 
 Within the central nervous system, chemical neurotransmission allows for 
rapid communication between neurons and target organs.  Once thought to be 
purely electrical in nature, the concept of chemical communication was originally 
hypothesized by Thomas Elliot at the turn of the 20th century, and later proven by 
the Nobel Prize winning work of Otto Loewi in the 1920s (Zigmond 1999).  
Chemical neurotransmission was finally accepted by the mid 20th century, and 
soon led to the identification of neurotransmitters that are responsible for the 
chemical communications.  Neurotransmitters are chemicals released from 
neurons into synaptic clefts that act on specific post-synaptic receptors, which in 
turn, activates signal transduction cascades. These signals can eventually lead 
to various biological and behavioral responses of the organism. The discovery of 
one neurotransmitter, dopamine (DA), by Arvid Carlsson was not without 
controversy.  Thought to be purely a metabolite of another neurotransmitter, 
norepinephrine, Dr. Carlsson’s work in the 1950s-1960s, which eventually lead to 
a Nobel Prize, proved DA was an important neurotransmitter involved in neural 
pathways controlling behaviors such as movement, motivation, and reward 
(Abbott 2007).   
  During the same time period of Dr. Carlsson’s important discoveries about 
DA, another future Nobel Prize winner, Julius Axelrod, was demonstrating how 
neurotransmission is regulated. The duration and strength of neurotransmission 
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is regulated by neurotransmitter transporter proteins, which remove 
neurotransmitters from the synaptic cleft (Hertting and Axelrod 1961).  Axelrod 
first demonstrated the concept of a reuptake mechanism by his experiments 
measuring the reuptake of neurotransmitters into sympathetic nerve terminals.  
Later, specific transporters were identified for several neurotransmitters, 
including dopamine.  Neurotransmitter transporters, such as the dopamine 
transporter (DAT), play a crucial role in maintaining homeostatic 
neurotransmission, and are responsible for regulating the precise temporal and 
spatial aspects of neurotransmission. 
DA signaling relies on a critical balance between release and removal of the 
neurotransmitter within synaptic clefts.  Therapeutic drugs and/or drugs of abuse, 
cause maladaptive changes in DA signaling, leading to addictive behaviors.  DAT 
is the primary site of action for psychostimulants such as, cocaine, 
methylphenidate, and amphetamine.  These drugs can alter the function and/or 
regulation of the transporter. Psychostimulant-induced modulation of uptake 
alters synaptic DA levels in the brain, and plays a critical role in mediating the 
mechanism of action of the drug.  Ethanol, one of the most widely abused drugs 
in society, is known to activate DA pathways in reward and reinforcement areas 
of the brain.  However, the effect of ethanol on DAT function and regulation is 
less clear.  The studies presented here explore the action of ethanol on DAT 
function, and the subcellular trafficking mechanisms that regulate the transporter.  
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1.1 Dopamine Transporter 
The neurotransmitter, dopamine (DA), plays a crucial role in the neural 
circuits that drive motor function, emotion, cognitive function, and reward 
behaviors.  Dependent on extracellular concentrations of the transmitter, DA 
signaling is maintained by a critical balance of DA release and removal from 
synaptic clefts (Torres et al. 2003b).  The duration and strength of DA 
neurotransmission is regulated by rapid removal of the transmitter via reuptake 
by DAT (Nelson 1998).  DAT is a member of the Na+/Cl- family of monoamine 
transporters including the γ-aminobutyric acid (GAT1), norepinephrine (NET), and 
serotonin (SERT) transporters (Torres et al. 2003b).  Altered DAT function and/or 
expression has been associated with several neurological disorders including 
Parkinson’s disease, Tourettes’s syndrome, attention-deficit / hyperactivity 
disorder (ADHD), depression, and drug abuse (Seeman and Niznik 1990, 
Dougherty et al. 1999, Laasonen-Balk et al. 1999, Vandenbergh et al. 2000, 
Cheon et al. 2004, Nutt et al. 2004, Mehler-Wex et al. 2006, Perona et al. 2008, 
Zhu and Reith 2008).  These findings highlight the importance of DAT in the 
pathophysiology of several neuropsychiatric disorders, and understanding 
transporter biology has increasingly significant clinical relevance in the treatment 





1.1.1 DAT localization 
Within the central nervous system, DAT is expressed in cell bodies, 
dendrites, axon membranes, and pre-synaptic dopaminergic terminals (Ciliax et 
al. 1995). There is also a regional heterogeneity of DAT expression within the 
brain with the highest level of expression reported in basal ganglia areas (Cerruti 
et al. 1993, Hall et al. 1999).  Within the basal ganglia, higher DAT levels have 
been reported in the nucleus accumbens (NAc) core compared with the shell 
(Nirenberg et al. 1997a).  This differential expression in the NAc underlies some 
of the functional differences and sensitivity between shell and core in response to 
psychostimulants (Pontieri et al. 1995, Nirenberg et al. 1997a).   In addition to the 
neuronal localization of the transporters, DAT has also been found in peripheral 
locations including the stomach, pancreas, and kidney (Eisenhofer 2001).    
On a subcellular level, immunogold staining revealed DAT is primarily 
localized in peri-synaptic areas outside of synaptic active zones (Nirenberg et al. 
1996, Hersch et al. 1997).  DAT labeling was prominent on the plasma 
membrane and smooth endoplasmic reticulum of dendrites and dendritic spines 
of the substantia nigra (SN) and ventral tegmental area (VTA), and along plasma 
membranes of varicose axonal regions in striatum (Nirenberg et al. 1996, 
Nirenberg et al. 1997b). The localization of DAT outside the synaptic active 
zones creates a concentration gradient of DA, drawing the transmitter out of the 
synaptic region (Nirenberg et al. 1996).  Therefore, the specific cellular 
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localization of the transporter contributes to the termination of dopaminergic 
neurotransmission.  
 
1.1.2 Molecular characterization of DAT 
The gene family of neurotransmitter transporters, solute carriers 6 (SLC6), 
was first identified in the early 1990s with the cloning of GAT1 and NET 
(Guastella et al. 1990, Nelson et al. 1990, Pacholczyk et al. 1991).  These 
important discoveries reveal significant amino acid sequence homology between 
the transporters and were soon followed by the isolation, cloning and 
characterization of the DAT gene (DAT1; SLC6A3) in rat, bovine, and human 
brain (Giros et al. 1991, Kilty et al. 1991, Shimada et al. 1991, Usdin et al. 1991).   
The human DAT1 gene was mapped to the distal end of chromosome five 
(5p15.3), and spans approximately 65kb containing fifteen exons (Giros et al. 
1992, Vandenbergh et al. 1992).  Further analysis of the gene revealed a 40bp 
region in the 3’ untranslated region (UTR) which contains a variable number 
tandem repeats (VNTR) polymorphism ranging from three to eleven copies 
(Vandenbergh et al. 1992).  Differences in the allelic frequency of this 
polymorphism can vary between global populations and ethnic groups, 
suggesting a potential link between genetic variations of the transporter and the 
the vulneribility of specific human populations to various neuropsychiatric 
disorders (Mitchell et al. 2000).   
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Association studies have implicated the 3’UTR VNTR polymorphism, and 
other single nucleotide polymorphisms (SNPs) with neuropsychiatric disorders in 
various human populations (Ueno 2003, Haddley et al. 2008).  For example, the 
polymorphism in the 3’UTR may confer vulnerability to alcoholism (Ueno et al. 
1999, Kohnke et al. 2005, Lind et al. 2009, Vaske et al. 2009) and/or contribute 
to the severity of withdrawal symptoms in alcoholics (Sander et al. 1997, Schmidt 
et al. 1998, Le Strat et al. 2008).  Additionally, SNPs in exon 2, intron 4, and in 
the 3’ UTR of the DAT1 gene have also been associated with alcohol 
consumption behaviors and withdrawal (Le Strat et al. 2008, Lind et al. 2009).  
However, several groups have found no relationship between alcohol use and 
the DAT1 gene 3’UTR VNTR polymorphism (Parsian and Zhang 1997, Franke et 
al. 1999, Foley et al. 2004).  The lack of consensus on the association of genetic 
polymorphisms with alcohol-related behaviors could be attributed to differences 
in populations and/or severity of disease between groups tested. 
While the polymorphic variants of the DAT1 gene may be important in 
conferring vulnerability to specific neuropsychiatric diseases, little is known of its 
transcriptional and translational regulation.  Since the 3’ VNTR polymorphism 
described above is in an untranslated region of the gene, several groups have 
suggested it may serve as a cis- or trans-acting transcriptional regulatory 
element (Heinz et al. 2000, Jacobsen et al. 2000, Mill et al. 2002, Fuke et al. 
2005).  Analysis of the 5’ region of the DAT1 gene suggests the presence of 
strong, non-specific promoter activity (Kouzmenko et al. 1997, Sacchetti et al. 
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1999).  However, since DAT has a highly restrictive tissue-specific expression 
indicating there are uncharacterized silencing elements in the distal 5’-flanking 
region (Sacchetti et al. 1999).  Additionally, the nuclear receptor, Nurr1, has been 
reported as a DAT1 transcription enhancer working through an unidentified 
response element (Sacchetti et al. 2001).  Enhancer elements were also 
identified in introns 9, 12, and 14.  Furthermore, differences in expression of two 
alleles of intron 14 suggested polymorphic variation in DAT1 gene expression 
(Greenwood and Kelsoe 2003).  Particular combinations of polymorphic variants 
in regions of DAT1 involved in transcription and translation of the gene could 
contribute to differences in populations with various neuropsychiatric diseases.   
 
1.2     Structure and Function of DAT 
Successful cloning of neurotransmitter transporters in the early 1990s, led 
to the evaluation and identification of DAT residues and structural motifs that are 
critical to its function. Proper substrate binding, translocation, and regulation of 
transporter function are dependent on DAT structure and cell membrane 
orientation.  DAT mediates DA uptake, and the inefficient uptake of 
norepinephrine (Giros et al. 1992), through a sodium symport mechanism.  Drugs 
of abuse, such as the psychostimulants cocaine and amphetamine target DAT 
and disrupt DA uptake by interacting with specific amino acids.  The identification 
of critical residues through various experimental and computational methods has 
advanced our understanding of transporter function and drug action.  
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1.2.1  DAT topology 
Human DAT contains 620 amino acids with an estimated size of 55-
90kDa, depending on glycosylation state (Giros et al. 1991).  Hydrophobicity 
analysis of DAT amino acid sequence, and the apparent lack of a signal 
sequence, revealed monoamine transporters are polytopic membrane proteins 
containing 12 putative transmembrane (TM) regions with intracellular N- and C-
termini (Giros et al. 1991, Kilty et al. 1991, Pacholczyk et al. 1991, Shimada et al. 
1991).   The transporter also contains a large extracellular loop between TM3 
and TM4, which contains several N-linked glycosylation sites (Li et al. 2004). The 
putative transmembrane domains, and intracellular localization of the termini 
were initially experimentally confirmed using immunoperoxidase and immungold 
electron microscopy (Hersch et al. 1997).   
An important breakthrough for monoamine transporter biology came in 
2005 with the elucidation of the crystal structure of a bacterial homologue 
(Aquifex aeolicus) of Na+/Cl- transporters, the leucine transporter (LeuTAa) 
(Yamashita et al. 2005).  Although there is only a 25% homology of sequence 
between LeuTAa and DAT, clusters of conserved amino acids are observed 
throughout the structure, including residues as critical for substrate binding and 
transporter function (Figure 1.1.A).  Furthermore, a recent computational 
modeling of DAT using the LeuTAa as a structural template, found the overall 
topological arrangements, the highly conserved TM regions, and substrate 
binding domains are almost completely superimposable (Indarte et al. 2008).     
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Yamashita et al. (2005) described the transporter as a shallow ‘shot glass’ 
shape with the opening of the glass facing the extracellular space, lacking a 
solvent accessible pore that spans the protein. The crystal structure was formed 
in complex with the leucine substrate and Na+ ions, and suggest the presence of 
extracellular and intracellular gates.  This finding supports the two gate theory (or 
‘alternating access model’) of transporter uptake dynamics previously purposed 
(Lester et al. 1996). The twelve TM regions are α-helical, and the core TM 
regions (TMs 1-10) appear to form a pseudo two-fold axis perpendicular to the 
membrane involving TMs 1-5 in one “fold” and TMs 6-10 in the second.  
Specifically the orientation of TMs 1-5 in the membrane are superimposable onto 
the orientation of TMs 6-10 by rotation of ~180° (Figure 1.1.B).  These novel 
findings could not be recognized with previous analysis of the amino acid 
sequence, and could have possible implications in understanding of substrate 








1.2.2 Electrophysiological properties of DAT 
 It has long been accepted that monoamine transporters require an active 
transport mechanism.  The thermodynamically uphill transport of substrate by 
DAT occurs down an electrochemical gradient, and requires the co-transport of 
two Na+ ions and one Cl- ion (McElvain and Schenk 1992, Chen and Reith 2003). 
The overall rate of uptake, which was estimated using electrochemical 
techniques, was found to be 2-5 DA molecules per second per DAT (Povlock and 
Schenk 1997, Cragg and Rice 2004).  At physiological pH, dopamine mostly 
Figure 1.1: DAT structure and topology. A. Structure of a neurotransmitter 
transporter, based on LeuTAa crystal structure.  B. Topological arrangement of 
DAT.  The ‘hinge’ regions of TM1 and TM6 are the primary areas that make up 
the putative substrate and Na+ binding pockets.  D79 and V152 are critical amino 
acids involved in substrate binding. The W84 and D312 residues have been 
identified as Na+ binding sites. G130 has also been identified as an ethanol 
sensitive site.  Neurotransmitter transporter structure was generated using 
MacPyMol 8 software. 
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exists in the positively charged form (Berfield et al. 1999); therefore the uptake 
process (DA+:Na+:Cl- = 1:2:1) produces the net import of two positive charges per 
uptake cycle.   
Neurotransmitter transporters have been shown to produce substrate-
induced currents (Sonders et al. 1997), capable of membrane depolarization 
(Carvelli et al. 2004) and a constitutive leak current (Ingram et al. 2002).  
Electrophysiological studies in midbrain dopamine neurons have revealed DAT 
may also produce uncoupled Cl- conductance, which can be blocked by uptake 
inhibitors.  These findings revealed a possible DAT-mediated alternative 
mechanism to produce neuronal excitability, and regulation of DA release 
(Ingram et al. 2002).  
 
1.2.3 Structural basis for substrate binding 
The identification of specific amino acids and networks of amino acids 
involved in substrate binding and translocation is critical in understanding the 
proper function and physiological properties of the transporter.  Evidence from 
chimeras between DAT and NET originally identified regions involved in selective 
substrate binding, cocaine affinity, translocation and ion dependence (Buck and 
Amara 1994, Giros et al. 1994, Buck and Amara 1995).  DAT and NET are the 
closest related transporters in the Na+/Cl- family of transporters, and have an 
overall 78% homology of their amino acid sequences (Kilty et al. 1991).  While 
DAT and NET can both remove DA and NE, their pharmacological profiles differ.  
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The carboxyl end of the transporter (TM9-carboxy-terminal tail) was originally 
identified as important in determining substrate affinity and steroselectivity for 
high affinity substrates (such as DA), while the regions between TM6 and TM8 
were identified as important in mediating the affinity of cocaine, a competitive 
inhibitor of DAT (Giros et al. 1994, Buck and Amara 1995).  Chimera studies 
between the slow bovine DAT and human DAT revealed TM3 also was a critical 
region in facilitating DA uptake and cocaine binding (Lee et al. 1998). However, 
many chimeras lack functional activity, limiting this approach in identifying 
specific networks of residues involved in transporter activity. 
Site-directed mutagenesis analysis provided additional insights into the 
structure/function of DAT.  In identifying the dopamine-binding site, researchers 
focused on hydrophobic and charged amino acids, which would bind 
monoamines, in the highly conserved TM regions.  Aspartic acid 79 in TM1 of 
human DAT, and the corresponding amino acid in NET and SERT, was found to 
be a site that is presumed to directly interact with monoamines (Figure 1.1.B).  
Mutation of D79, inhibits binding of substrate without altering cell surface 
expression of the transporter (Kitayama et al. 1992).  Investigation of the TM3 
region involvement in substrate binding, found valine 152 (Figure 1.1) in human 
DAT crucial in interacting with DA (Lee et al. 2000).  Tryptophan 84 and aspartic 
acid 313 in TM1 and TM6, respectively, were found to play a role in Na+ 
interaction (Figure 1.1.B).  Mutations at W84 and D313 suggested Na+ interaction 
with the transporter facilitates substrate binding and translocation (Chen and 
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Reith 2003). Further site-directed mutation studies have revealed other amino 
acids that may play a critical, but not clearly defined, role in transporter function. 
These earlier site-directed mutational findings are in agreement with the 
recent computational analysis of DAT based on the LeuTAa crystal structure 
(Yamashita et al. 2005, Indarte et al. 2008).  In these studies, distinct regions of 
TM1 and TM6 were found to be the probable dopamine binding sites, and sites of 
Na+ interaction.  The structures indicate TM1 and TM6 are partially unwound in 
center of α-helices, forming short hinge-like regions and exposing the main chain 
carboxyl regions (Figure 1.1.B).  This area, along with interactions with TM3 and 
TM8, form a binding pocket for DA and the two Na+ ions (one Na+ at the hinge 
region of TM1, and the other at the hinge region of TM6).  The D79 residue, 
previously identified as critical in substrate binding (Kitayama et al. 1992), 
resides in the hinge region of TM1, the area that makes up part of the substrate-
binding pocket.  The human DAT structure model suggests the side chain of 
V152 in TM3, also previously identified as a critical residue (Lee et al. 2000), 
directly interacts with DA in the binding pocket (Indarte et al. 2008).  
Furthermore, the putative site of Na+ interaction on central TM1 and TM6 (Figure 
1.1.B) are in the regions purposed by Chen and Reith (2003).  Valence 
calculations of the crystal structure yielded sodium-specific valence for these 




1.2.4 Structural basis for substrate translocation 
In addition to their electrophysiological properties, ion channels and 
neurotransmitter transporters display gating properties with selective high-affinity 
binding sites for substrate and ions.  However, the gating properties of 
neurotransmitter transporters, unlike ion channels, appear to contain two putative 
gates at the intracellular and extracellular faces of the transporter (Lester et al. 
1996, Yamashita et al. 2005). Mutational and computational analysis of DAT 
permeation have identified putative networks of residues which contribute to 
gating of the transporter and allow for conformational changes to occur during 
the substrate translocation process.   
The outward facing conformation of DAT is stabilized by interactions of an 
intracellular network of residues.  This intracellular gate occludes the substrate 
and ion binding sits from the cytoplasm, and is composed of interconnection of 
the N-terminus/TM1 (R60) region with IL3/TM6 (V259, S334, Y335) and TM8 
(E428 and D436) region on of the transporter (Loland et al. 2002, Loland et al. 
2004, Kniazeff et al. 2008).  The R60 forms a putative salt bridge with D436 and 
a cation-π interaction with Y335.  Mutations of these highly conserved residues 
block DA transport by inhibiting DAT conformational changes during the 
translocation process (Loland et al. 2004).  This network of amino acids likely 
serve to stabilize the substrate binding pocket formed by TM1 and TM6 and the 
outward facing conformation (Yamashita et al. 2005, Kniazeff et al. 2008).  The 
less complex extracellular gate, which forms with the inward facing conformation, 
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is composed of a putative salt bridge between R85 and D476 in TM1 and TM 10, 
respectively (Yamashita et al. 2005, Huang and Zhan 2007). 
Reorganization of DAT structure during the substrate translocation 
process is initiated by the interaction of Na+ in the core of the transporter at the 
unwound and flexible regions of TM1 and TM6 (Chen et al. 1999, Yamashita et 
al. 2005).  Binding of the Na+ ions likely reorganizes the internal DAT structure, 
and stabilizes the structure of the substrate-binding pocket, allowing dopamine to 
bind at TM1 and TM6 (Yamashita et al. 2005, Indarte et al. 2008).  Recent 
modeling of DAT suggested a low-affinity, secondary substrate docking site at 
the extracellular interface of TMs 1, 6, 10, 11 and EL3 and 4 (Indarte et al. 2008).  
This area may serve as a molecular ‘waiting room’ for substrate, and substrate 
enters the primary binding site with the presence of the ion interactions within the 
transporter. While the conformational changes that occur after the binding of the 
substrate have yet to be completely understood, it is thought the flexible 
unwound regions of TM1 and TM6 act as joints to open and close the two 
transporter gates (Yamashita et al. 2005).  In addition to the highly conserved 
substrate binding sites and TM region gates, surface exposed areas of the 
transporter have also been shown to indirectly maintain the open or closed 
configurations.  The intracellular and extracellular ends of the TM2 region bend 
inwards towards TM1 and TM6 forming a pincer-like configuration.  The 
interaction between the pincer regions and TM1 and TM6 play an indirect role in 
substrate and cocaine binding (Sen et al. 2005).  Furthermore, evidence from the 
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LeuTAa crystal structure suggest transporter loops (IL1, EL2, and EL4) shift 
during substrate translocation and possibly contribute to opening and closing the 
permeation pathway.   
 
1.2.5 DAT glycosylation 
Substrate binding, translocation, and trafficking of DAT can be influenced 
by post-translational modification.  Prior to the cloning of the transporter, 
researches investigated the molecular characteristics of DAT using photoaffinity 
binding in rat brain, and found DAT was heavily glycosylated (Grigoriadis et al. 
1989, Sallee et al. 1989).  Further investigation with deglycosylation enzymes 
suggested the carbohydrate moiety of the transporter is asparagine-linked (N-
linked) with high amounts of sialic acid (Lew et al. 1991).  DAT contains three 
putative glycosylation sites on the large EL2 region, N181, N188, and N205 
(Figure1.1.B) (Torres et al. 2003a, Li et al. 2004).  Comparisons of DAT 
molecular mass between brain regions, developmental stage, and species 
revealed a microheterogeneity of transporter glycosylation, suggesting cell type 
specificity in post-translational processing (Lew et al. 1992, Patel et al. 1994, 
Vaughan and Kuhar 1996).  These differences in glycosylation state alter the 
functional expression of DAT on the cell surface and may account for differences 
in DA uptake kinetics between tissues and cell types (Patel et al. 1993, Patel et 
al. 1994, Povlock and Schenk 1997).  Pharmacological deglycosylation or point 
mutations of the N-linked glycosylation sites, decreases surface expression of 
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the transporter, increases endocytosis of the immature DAT (non-glycosylated 
transporter), alters inhibitor (including cocaine) sensitivity, and impairs DA uptake 
(Daniels and Amara 1999, Torres et al. 2003b, Li et al. 2004).  However, 
complete mutation of the three N-linked glycosylation sites revealed the small 
portion of immature DAT expressed on the cell surface is functional (Torres et al. 
2003a, Li et al. 2004).  These studies suggest glycosylation plays a role in proper 
transporter trafficking and folding, but is not required for function.     
 
1.2.6 DAT oligomerization 
The structural and functional characteristics of DAT outlined above 
describe the transporter as a single molecular unit, however DAT and other 
monoamine transporters may exist as oligomers.  Early radiation inactivation 
studies using rat synapotosomes, which estimated the size of the transporter 
unit, found DAT size was larger than the estimated 70 kDa, suggesting DAT 
dimerization (Berger et al. 1994).  Chemical crosslinking, fluorescence resonance 
energy transfer (FRET) microscopy, and co-immunoprecipitation studies 
confirmed DAT homo-oligmerization (Hastrup et al. 2001, Sorkina et al. 2003, 
Torres et al. 2003a), similar to SERT, GAT1, and NET (Kilic and Rudnick 2000, 
Schmid et al. 2001, Scholze et al. 2002).  Cystine crosslinking studies 
determined DAT exists on the cell surface as a dimer of dimers, with the 
extracellular interfaces of TM6 and TM4 forming symmetrical interactions with 
other DAT units (Hastrup et al. 2003).  Mutational analysis of the leucine zipper 
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region in TM2 suggested this region was also involved in a dimer interface 
(Torres et al. 2003a).  However, recent crystal structure analysis found TM 2, 4, 
and 6 are part of the transporter core, and may not be readily accessible to 
extensive contacts with other transporters (Yamashita et al. 2005, Indarte et al. 
2008).  Furthermore, a recent study using substituted cystetine accessibility 
method (SCAM) found the leucine zipper in TM2 may not be involved in 
dimerization, but actually plays an indirect role in cocaine binding with its 
interaction with TM1 and TM6, areas involved in substrate binding (Sen et al. 
2005).  Yamashita et al. (2005) suggest the more peripheral TM11 and TM12 are 
likely candidates involved in oligomerization, similar to observations of SERT 
oligomers (Just et al. 2004).    
While the role of oligomerization on transporter function is unclear, FRET 
studies of human DAT have shown that the transporter exists in oligomers in all 
cellular compartments occupied by DAT, and may be required for trafficking 
(Sorkina et al. 2003).  Recent studies have also suggested substrates that act on 
the transporter, including dopamine and amphetamine, may modulate 
oligomerization after post-translational processing (Chen and Reith 2008).  The 
researche’s noted that the substrates dissociated dopamine transporter 
oligomers after endocytosis.  Inhibition of endocytosis halted the dissociation of 
DAT complexes.  These studies not only indicate the possible regulation of 
oligomerization, but also suggest oligomerization plays a role in endocytic 
trafficking and / or recycling of the transporter. 
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1.3 Effects of Drugs of Abuse on DAT 
The reinforcement of drugs of abuse is partly mediated through their actions 
on the dopaminergic system.  Several of these drugs are known to target the 
dopamine transporter, and interfere with DA uptake.  This modulation of uptake 
alters synaptic DA levels in the brain, contributing to the psychoactive and 
addictive effects of the drugs.  DAT is the primary site of action for 
psychostimulants, such as cocaine and amphetamine.  However, the effect of 
alcohol on the transporter is under debate.   
 
1.3.1 Psychostimulant action on DAT function 
Pyschostimulants are known to mediate their effects by altering dopamine 
uptake.  Cocaine, a potent competitive inhibitor of DAT, causes an accumulation 
of DA and overstimulation of DA receptors within the synapse (Nestler 2005).  In 
the DA neuron-rich mesolimbic brain regions, the excess DA elicits states of 
euphoria and pleasure.  Repeated use produces loss of control and compulsive 
response to drug related cues (Hyman et al. 2006).   The importance of the 
transporter in the reinforcing properties of cocaine has been observed in animal 
models.  DAT knockout mice, in a cocaine self-administration paradigm, have a 
significantly attenuated response and a decreased preference to cocaine (Giros 
et al. 1996).  These findings were supported by evidence from transgenic mice 
that express a cocaine-insensitive DAT.  The reinforcing effects of the drug were 
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completely abolished in these transgenic animals compared to mice expressing 
the wild-type form of the transporter (Chen et al. 2006).   
 The identification of DAT as the ‘binding receptor’ of cocaine was well 
established prior to our understanding of the transporter structure (Ritz et al. 
1987).  Site-directed mutagenesis identified residues in TM1 (D79 and W84) and 
TM6 (D313) as critical residues involved in the binding of cocaine (Chen et al. 
2001, Ukairo et al. 2005).  With the information gained from the LeuTAa  crystal 
structure, it was suggested that cocaine and DA binding sites overlap in the core 
of the transporter (Beuming et al. 2008).  However, other studies indicate cocaine 
binding occurs on TM regions involved in DA binding, but in a more extracellular 
location, possibly blocking the DA translocation pathway (Vaughan et al. 2007).  
The recent computational model of DAT, suggesting a secondary docking site for 
transporter substrate and inhibitors, supports this idea (Indarte et al. 2008).   
 While cocaine exerts its effects on DAT by competitive inhibition, 
amphetamine increases synaptic DA concentrations by acting as a transporter 
substrate and inducing a reverse transport of the neurotransmitter (Fischer and 
Cho 1979, Sulzer et al. 1993, Sulzer et al. 1995, Sulzer et al. 2005).  
Amphetamines are widely abused; however, they have also long been used in 
the pharmacological management of several neurological disorders such as 
ADHD (Zaczek et al. 1991). Although the exact mechanism of transmitter efflux is 
unknown, however, evidence suggest amphetamine enters the cell as a DAT 
substrate, interacting with residues within the DA substrate-binding site (Beuming 
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et al. 2008).  Upon cellular entry, the drug releases vesicular stores of DA, 
promoting reverse active transport via an inward-facing DAT (Zaczek et al. 1991, 
Fon et al. 1997, Erreger et al. 2008).  Delineating the mechanism of action and 
binding of psychostimulants on the transporter aides researchers efforts in the 
development of pharmacological treatments for addiction, depression, and other 
neurological diseases.   
 
1.3.2 Ethanol action on DAT 
     Alcohol (ethyl-alcohol; ethanol) is one of the most common drugs of 
abuse in society, and exerts its effects on several neurotransmitter systems, 
including dopamine.  Like psychostimulants, ethanol induces an increase in 
synaptic DA, which is thought to mediate the reward and reinforcing effects of the 
drug (Gonzales et al. 2004).  It has been established ethanol increases synaptic 
dopamine concentrations by inducing an increase of firing of DA neurons (Brodie 
et al. 1990, Weiss et al. 1993, Yim et al. 1997, Brodie and Appel 1998, Yim et al. 
1998).  As described above, several groups have also linked a polymorphism in 
the 3’ UTR of the DAT1 gene to alcoholism and/or to the severity of  the 
symptoms of alcohol withdrawal (Sander et al. 1997, Schmidt et al. 1998, Kohnke 
et al. 2005, Le Strat et al. 2008).  However, the effects of ethanol on DAT 
function are controversial.   
Dopamine release and synaptic concentration in vivo are commonly 
measured by electrochemical methods, including microdialysis, voltametry, and 
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chronoamperometry.  Researchers have utilized these methods to also measure 
DA clearance in awake and anesthetized animals.  The no-net-flux microdialysis, 
which has been reported to quantitatively measure transporter activity, have 
suggested the ethanol-induced increases in rat NAc is not due to an inhibition of 
DAT activity (Yim and Gonzales 2000). Further in vivo investigation of transporter 
activity by voltametry or chronoamperometry has suggested acute ethanol 
increases (Wang et al. 1997, Sabeti et al. 2003), decreases (Robinson et al. 
2005), or has no effect (Budygin et al. 2001, Mathews et al. 2006) on DAT 
activity.  Recently, chronic ethanol has been shown to increase DA uptake in rat 
NAc (Budygin et al. 2007).  
The in vitro effects of ethanol on DA uptake suggest chronic and acute 
exposure potentiates DAT-mediated DA uptake. An increase in DA uptake and 
surface expression was reported in rats under chronic ethanol exposure 
(Rothblat et al. 2001, Carroll et al. 2006). When DAT is expressed in Xenopus 
oocytes, acute ethanol exposure increased DA uptake and transporter-
associated currents in a time- and concentration-dependent manner (Mayfield et 
al. 2001, Maiya et al. 2002).  Furthermore, surface binding with a radioligand 
cocaine derivative, suggested ethanol induced an increase in the number of 
transporters on the cell surface (Mayfield et al. 2001). Results from these studies 
suggest ethanol potentially alters DAT function by modulating transporter 
trafficking.   
 23 
Acute ethanol exposure can also alter other neurotransmitter transporters.  
When expressed in HEK-293 cells, glycine transporters (GLYT1 and 2) are 
differentially affected by high concentrations of ethanol. Ethanol enhances 
GLYT1 function, while GLYT2-mediated uptake is inhibited (Nunez et al. 2000).  
Exposure to acute ethanol also enhances SERT uptake in synaptosomes 
prepared from rat cortical brain regions (Alexi and Azmitia 1991).  The closest 
related transporter to DAT in structure and function, NET, has been shown in 
several studies in vitro to be inhibited by acute ethanol (Lin et al. 1993, Lin et al. 
1997, Maiya et al. 2002).  The opposing effects of acute ethanol on DAT and 
NET led researchers to identify ethanol-sensitive sites on DAT by generating 
chimeras between the two transporters (Maiya et al. 2002).  These studies 
revealed IL1, which only differs in NET and DAT by four amino acids (DAT 
residues; F123, G130, I137, L138), was a critical area involved in the ethanol 
sensitivity of DAT (Figure 1.1.B). Of these residues, G130 and I137 appear to 
mediate the ethanol sensitivity of DAT.  Mutation of either residue to the 
corresponding NET residue abolished DAT sensitivity to ethanol while 
maintaining the transporter’s function when expressed in Xenopus oocytes.  
However, the exact mechanism of ethanol action on DAT is unclear. 
 
1.4 DAT Functional Regulation 
Redistributing the number of transporters expressed on the cell surface 
primarily regulates DAT function. This dynamic trafficking of DAT occurs in a 
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constitutive or regulated manner, and allows for rapid removal of transmitter.  
The transporters recycle between endosomal pools, which are localized near the 
plasma membrane, and the cell surface.  Various steps in the DAT trafficking 
pathway can be regulated by second messenger systems, substrate, and 
pharmacological modulation.   
 
1.4.1 Constitutive DAT trafficking      
DAT proteins are synthesized and processed in the endoplasmic reticulum 
(ER) and Golgi complex.  The C-, but not N-, terminus of the transporter is critical 
for export from the ER (Torres et al. 2001, Miranda et al. 2004).  An interaction 
between the last three amino acids in the C-terminus of the transporter (LKV) 
and the PDZ binding domain of the PICK1 (protein that interacts with C kinase), 
an adaptor protein, has been shown to be important in ER-to-plasma membrane 
trafficking and subcellular localization of the transporter (Torres et al. 2001).  
However, others have found that while the C-terminal tail is crucial for subcellular 
targeting of the transporter, the PDZ domain of DAT and the PICK1 interaction is 
not required, nor was the interaction confirmed in a recent analysis of the DAT 
trafficking proteome (Bjerggaard et al. 2004, Maiya et al. 2006).   
After delivery to the cell surface, DAT is internalized by a clathrin / 
dynamin-dependent mechanism into endosomal pools, involving the clathrin 
adaptor proteins epsin, Eps15 (epidermal growth factor pathway substrate clone 
15) and Eps15R (Eps15-related protein) (Daniels and Amara 1999, Sorkina et al. 
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2005, Sorkina et al. 2006).  DAT lacks classical intenalization signal motifs such 
as tyrosine- or dileucine-based sequences.  However, a recent chimera study 
producing gain-of-function mutants between the N- and C- terminal tails of DAT 
and the transferrin receptor (TfR) or interleukin 2α receptor, respectively, 
suggested a constitutive endocytic signal in the C-terminus of the transporter 
(Holton et al. 2005).  This nonclassical signal motif, which contains DAT residues 
587-596, is conserved in other monoamine transporters (GAT1, SERT, and 
NET).  The C-terminus also contains an overlapping protein kinase C (PKC) -
sensitive endocytic signal (Holton et al. 2005, Boudanova et al. 2008b).   
Studies of transporter internalization, induced and accelerated by the 
activation of PKC by phorbol 12-myristate 13-acetate (PMA), suggest DAT 
localized in endosomal pools can be targeted to degradation in lysosomes by 
ubiquitylation of lysine residues in the N-terminus (Miranda et al. 2005).  
Ubiquitylation is mediated by the E3 ubiquitin ligase, Nedd4-2 (neural precursor 
cell expressed, developmentally downregulated 4-2) (Sorkina et al. 2006).  While 
it is believed DAT can be constitutively ubiquitinated and degraded in lysosomes, 
ubiquitin-mediated trafficking has only been examined in PMA-induced PKC 
activated cells (Sorkina et al. 2006).  Early observations of DAT internalization in 
MDCK cells suggested internalized transporters are targeted to the lysosomal 
degradation pathway (Daniels and Amara 1999). However, several other studies 
have shown the majority of DAT actually remains in early endosomal pools, and 
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recycles back to the cell surface (Melikian and Buckley 1999, Loder and Melikian 
2003).    
Endosomal (or endocytic) recycling of the transporter allows for the rapid 
and efficient fine-tuning of dopaminergic signaling (Figure 1.2).  Basal recycling 
rates are relatively modest, with a half-life (t1/2) of expression on the cell surface 
of ~13 minutes, suggesting a rate of ~3-5% of DAT internalized per minute in 
heterologous cell expression lines (Loder and Melikian 2003, Li et al. 2004).  
These rates are comparable to constitutive recycling rates of GAT1 (Deken et al. 
2000, Wang and Quick 2005). Analysis of endogenous cystine residues in the 
second extracellular loop suggest this area may play a key role in transporter 
expression on the cell surface (Wang et al. 1995).  However, little is known of 
residues, protein-protein interactions, and/or cell signaling pathways involved in 
DAT insertion onto the membrane during constitutive recycling.   
 
1.4.2 Regulated DAT trafficking 
Regulation of dynamic trafficking of DAT plays a key role in facilitating the 
regulation of dopaminergic signaling (Mortensen and Amara 2003). Cell surface 
DAT levels can be acutely modulated by several second messenger pathways or 
pharmacologically by various drugs, including psychostimulants. These 
modulators alter specific steps or multiple steps of the endosomal recycling 
pathway (insertion and/or internalization) resulting in changes in transporter 
surface localization. Emerging evidence from these studies investigating intrinsic 
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or pharmacologically regulated transporter trafficking has also provided additional 
information on the cellular mechanisms involved in the DAT recycling pathway. 
 
1.4.2.1 Regulation of DAT by kinase activity 
The activation of several kinases, via second messenger systems, has 
been shown to alter DAT functional regulation.  The regulation of DAT trafficking 
by phorbol ester-activated PKC has been well documented, and has been 
consistently shown to reduce the activity of the transporter in several transfected 
cell lines and synaptosomal preparations (Zhu et al. 1997, Daniels and Amara 
1999, Melikian and Buckley 1999).  PKC-mediated inhibition of DA uptake is a 
result of a downregulation of DAT surface expression, and not a change in 
transporter activity (Daniels and Amara 1999).  The surface downregulation 
occurs by a PKC-induced increase in internalization by a clathrin/dynamin 
dependent mechanism and a parallel attenuation in transporter insertion into the 
membrane (Loder and Melikian 2003).  Endocytosis of the transporter is 
accelerated by PKC activation, but is not required for constitutive internalization 
of DAT (Granas et al. 2003).  Deletion of the N-terminus of the transporter 
abolishes PKC-induced regulation, but has no effect on DAT-mediated DA 
uptake.   
The exact mechanism of PKC action on DAT is unclear.  Evaluation of the 
DAT sequence suggests the presence of several consensus phosphorylation 
sites for PKC, PKA, and Ca2+ calmodulin kinase (Giros et al. 1991, Kilty et al. 
 28 
1991, Shimada et al. 1991, Usdin et al. 1991).  However, while PKC activation 
increases DAT phosphorylation (Vaughan et al. 1997), mutagenesis analysis 
showed the consensus sites were not essential in mediating PKC-induced 
regulation of DAT (Chang et al. 2001).  These results suggest PKC-mediated 
functional regulation occurs in an indirect manner involving other accessory 
proteins or clathrin / dynamin activation pathways to induce internalization.   
The PKC pathway has also been proposed to play a role in the molecular 
actions of amphetamine on DAT.  Exposure to PKC inhibitors blocked 
amphetamine-induced efflux of DA in rat striatal slices in a DAT and Ca2+-
dependent manner (Kantor et al. 1999).  When injected directly into rat NAc, PKC 
inhibitors also blocked amphetamine-mediated locomotor behavior (Browman et 
al. 1998).  However, a recent study investigating amphetamine-induced 
trafficking of the transporter in stably expressing PC12 cells suggested the 
effects of the psychostimulant  were independent of PKC activity (Boudanova et 
al. 2008a).  Mutation of residues in DAT required for PKC-stimulated 
internalization had no effect on amphetamine-related alterations in transporter 
trafficking.  These studies suggest amphetamine alters DAT trafficking in a direct 
manner, and will be discussed further in the next section.   
In addition to regulation by PKC, other kinase signaling cascades have 
also been shown to regulate DAT-mediated DA uptake.  Stimulation of the 
adenylyl cyclase-cyclic AMP (cAMP)-PKA pathway by forskolin or cAMP 
analogues potentiate DA uptake in rat striatal synaptosomes (Batchelor and 
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Schenk 1998, Page et al. 2000).  Inhibition of phosphatidylinositol-3-kinase (PI 3-
K) or mitogen-activated protein kinase (MAPK), which can be activated 
downstream of PI 3-K, decreased DA uptake and cell surface expression of DAT 
in rat striatal synaptosomes and transfected HEK-293 cells (Carvelli et al. 2002, 
Moron et al. 2003).  Recent studies investigating the MAPK phosphatase (MKP3) 
action on the transporter activity suggested the phosphatase enhances DAT 
activity by possibly blocking dynamin-dependent internalization (Mortensen et al. 
2008).   Results discussed in this section suggest phosphorylation events may be 
important in regulation of the transporter, however the requirement of 
phosphorylation in all DAT regulation remains unclear.    
 
1.4.2.2 Pharmacological and substrate-induced regulation of DAT 
Therapeutic drugs and drugs of abuse have also been shown to modulate 
DAT function by altering trafficking of the transporters.  The effects of several of 
these drugs, such as amphetamines, are mediated by acting as DAT substrate.  
Amphetamine is often prescribed for adult ADHD; however the psychostimulant 
is commonly abused, and can alter normal dopaminergic signaling by its actions 
on the transporter.  DAT substrates, DA and amphetamines, have been shown to 
regulate transporter expression on the cell surface. Both substrates decrease 
DAT-mediated DA uptake by causing an increase in internalization of the 
transporter in cell expression systems and rat striatal synaptosomes (Saunders 
et al. 2000, Chi and Reith 2003).  Results from in vivo voltammetry experiments 
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have also shown a decrease in transporter mediated DA clearance by DA and 
amphetamine (Gulley and Zahniser 2003).    
Amphetamines act to block uptake of the endogenous substrate, and 
promote DA efflux, as described above (Zaczek et al. 1991, Fon et al. 1997, 
Beuming et al. 2008, Erreger et al. 2008).  These actions are also mediated by 
modulating DAT endosomal trafficking.  After an initial rapid delivery (< 3 minute) 
to the cell surface (Johnson et al. 2005, Furman et al. 2009), amphetamine has 
been shown by several studies, in vivo and in vitro, to cause DAT to sequestered 
in intracellular compartments (Sandoval et al. 2000, Sandoval et al. 2001, Kahlig 
et al. 2004, Kahlig et al. 2006).  Amphetamine-regulated trafficking results in a 
suppression of transporter insertion and stimulation of endocytic rates, causing 
an overall decrease in surface levels of DAT (Boudanova et al. 2008a).  The 
psychostimulant had no effect on global endosomal recycling or PKC-mediated 
regulation.  The overall effects of amphetamine are elevated extracellular DA 
levels, which allows for continued receptor stimulation.  
Other psychostimulants and therapeutic agents, including cocaine, 
bupropion (Wellbutrin), and methylphenidate (Ritalin) elevate synaptic DA levels 
by acting as an inhibitor of DAT (Dwoskin et al. 2006, Zahniser and Sorkin 2009).  
Cocaine and methylphenidate increase the number of DAT binding sites on the 
cell surface (Zahniser and Sorkin 2009). Cocaine has also been shown to elevate 
transporter levels on the cell surface directly in transfected cell lines using 
immunofluorescence and biotinylation (cell surface protein labeling) (Little et al. 
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2002).  Consistent with the upregulation of surface localization, DA uptake 
kinetics suggested acute cocaine exposure increased uptake velocity (Vmax) 
without altering DA binding affinity of the transporter (KM) in rat NAc 
synaptosomes, and increased DA clearance in the striatum of anesthetized rats 
(Daws et al. 2002).  These results suggest cocaine, and perhaps other DAT 
inhibitors, alter DAT trafficking, however it is yet to be determined if elevated 
surface levels of the transporters are due to an increase in insertion or a 
decrease in internalization. 
Although a considerably large number of studies have investigated the 
actions of psychostimulants on DAT, less is known of the effects of some of the 
more commonly abused drugs such as nicotine and ethanol.  Nicotine increases 
synaptic DA levels by activation of nicotinic acetylcholine receptors (nAChR).  
However, there is also evidence nicotine alters DAT function (Hart and Ksir 
1996).  Recent biotinylation and electrochemical studies investigating nicotine’s 
mechanism of action on DAT regulation suggest nicotine increases DAT surface 
expression in the prefrontal cortex, but not striatum, via a nAChR-dependent 
mechanism (Zhu et al. 2009).    The mechanism of nicotine-induced DAT surface 
localization has yet to be determined. 
Ethanol is known to modulate the dopaminergic system, mediating the 
rewarding and reinforceing effects of ethanol.  However, the action of ethanol on 
DAT is controversial, as described above.  Chronic exposure to ethanol alters 
DAT binding density in human alcoholics experiencing relapse, ethanol preferring 
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monkeys, and rat striatal brain tissue (Tiihonen et al. 1995, Mash et al. 1996, 
Jiao et al. 2006).  Less is known of the acute action of ethanol on DAT.  Several 
in vitro studies in DAT expressing Xenopus oocytes suggest ethanol potentiates 
transporter function, and this increase in uptake is accompanied by an increase 
in DAT binding density (Mayfield et al. 2001, Maiya et al. 2002).  However, others 
have found ethanol effects on the transporter are mediated through a neural-
specific pathway (Ho and Segre 2001).  Direct evidence of ethanol action on DAT 
surface expression and regulation in mammalian systems has yet to be 
determined.   Determining the mechanism of action of ethanol on DAT function 
and regulation is essential in understanding ethanol-induced changes on 







1.5 Research Aims 
 Electrophysiological and DA binding experiments in DAT expressing 
Xenopus oocytes suggest ethanol potentiates DAT-mediated DA uptake 
(Mayfield et al. 2001).  The sensitivity of the transporter appears to be mediated 
by residues in the first intracellular loop of the transporter (Maiya et al. 2002).  
The absence of consensus sites for PKC or PKA phosphorylation in this loop 
Figure 1.2: Intracellular DAT trafficking.  After synthesis and post-translational 
processing, (a) transporters are delivered to the cell surface.  DAT is internalized via 
dynamin- and clathrin-dependent mechanisms where they are predominantly localized 
to (b) endosomal recycling pools near the plasma membrane.  Transporters are 
dynamically trafficked (c) to and (d) from the membrane to rapidly regulate extracellular 
dopamine level. 
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suggests ethanol may directly regulate transporter function through a traffcking-
dependent mechanism. However, when expressed in neuronal or non-neuronal 
mammalian cell systems, others have suggested ethanol modulates DAT 
function though a neural-specific pathway (Ho and Segre 2001).  We hypothesize 
ethanol potentiates DAT function in all mammalian cells by directly modulating 
transporter trafficking.  Direct regulation of transporter function by ethanol may 
provide a rapid regulatory mechanism for ethanol-induced increases in synaptic 
DA concentrations. The objective of this study is to characterize ethanol effects 
on DAT function and regulation in mammalian cell systems and identify the 
mechanism of ethanol action on transporter regulation. 
  
1.5.1 Aim 1: The effects of ethanol on DAT function in mammalian 
cell systems 
Previous studies in DAT-expressing Xenopus oocytes suggest ethanol 
potentiates DAT function.  The objective of this aim is to determine if similar 
changes are seen in neuronal and non-neuronal mammalian cell expression 
systems, and determine the specificity of ethanol action on the transporter.  
Mutant transporters (G130T), found to be insensitive to ethanol when expressed 
in Xenopus oocytes, will also be used as a tool to determine the specificity of 
ethanol action on the transporter.   Dopamine upake and kinetics will be analyzed 
in the DAT-expressing cells to determine ethanol action on DAT function. Surface 
expression of DAT after ethanol exposure will be measured using cell surface 
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biotinylation assays.  We hypothesize ethanol potentiates DAT function, and 
elevates DAT surface expression in a directly rather than through cell-specific 
pathways, in mammalian cell expression systems. 
 
1.5.2 Aim 2: Ethanol action on DAT endosomal recycling 
 Preliminary experiments suggest ethanol enhances DAT cell surface 
expression.  The objective of aim two is to determine the subcellular mechanism 
underlying ethanol-mediated regulation of DAT.  DAT or G130T DAT (ethanol 
insensitive-mutant) will be stably expressed in HEK-293 cells, and surface 
expression will be compared to confirm ethanol-induced changes are trafficking 
mediated.  The effects of ethanol on the DAT endosomal recycling pool size, and 
the rates of cell surface insertion and internalization will be measured using 
modified and reverse biotinylation assays.   We hypothesize ethanol induces 
increases in DAT cell surface expression by altering the rates of endosomal 
recycling.  
 
1.5.3 Aim 3:  Characterization of the first intracellular loop of DAT in cell 
membrane trafficking 
Chimera studies between DAT and NET in Xenopus oocytes suggest the 
first intracellular loop is critical in DAT trafficking and ethanol-mediated regulation 
of transporter trafficking.  NET and DAT differ by four amino acids in the loop, 
DAT residues F123, G130, I137, and L138.  Mutation of these residues to the 
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corresponding NET residues (IGLF DAT) abolished DA uptake and DA binding in 
Xenopus oocytes, suggesting the first intracellular loop is critical for DAT-specific 
trafficking.  The objection of aim three is to characterize the function and cellular 
localization of the IGLF DAT in mammalian cells.  Characterization of the IGLF 
mutant may be important in future studies identifying protein interactions critical 
in DAT trafficking.  We hypothesize IGLF DAT uptake function will be abolished 
as a result of deficiencies in cell membrane trafficking.   
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Chapter Two:  Materials and Methods 
This chapter describes the materials and methods used to address specific 
aims one, two, and three presented in the following chapters. 
 
2.1 Methods for Chapter Three (Specific Aim One) 
The following section was published in Alcohol, vol 42, issue 6: 499-508, 
2008, and is reprinted with permission from Elsevier.   
 
2.1.1 Site-directed mutagenesis 
The ethanol insensitive mutant (G130T DAT) (Maiya et al. 2002) was 
constructed from wild-type human DAT cDNA subcloned in a pBK-CMV vector 
(Stratagene, La Jolla, CA) using the QuikChange site-directed mutagenesis kit 
(Stratagene) to replace the glycine at position 130 with a threonine.  Both wild-
type and G130T DAT cDNA constructs were subcloned into the mammalian 
expression vector pEGFP-C1, and transfected into HEK-293 or SK-N-SH 
mammalian cells.  The constructs contained an enhanced green fluorescent 
protein (eGFP) marker to confirm DAT expression by visualization with 
fluorescent microscopy.  Mutagenesis was verified by sequence analysis 





2.1.2 Cell culture and transient tranfections 
HEK-293 and SK-N-SH cells were purchased from ATCC (Manassas, 
VA).  Cells were maintained in a humidified atmosphere at 37°C and 5% CO2 in 
HEK-293 growth media (Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Atlanta 
Biologicals, Lawrenceville, GA) and 0.1% Penicillin / Streptomycin (Sigma-
Aldrich, St. Louis, MO)) or SK-N-SH growth media (Modified Eagle Medium 
(MEM) (Gibco, Carlsbad, CA) supplemented with 10% FBS and 0.1% Penicillin / 
Streptomycin).  For uptake and kinetics assays, cells were split 24 hours prior to 
transfection into poly-D-lysine-coated 12-well plates (Becton-Dickinson, Bedford, 
MA) at a density of 0.5x105 per well.  Cells were transiently transfected with 
either eGFP wild-type human DAT or eGFP G130T DAT cDNA for 2 hours using 
Lipofectamine/PLUS reagents (Invitrogen, Carlsbad, CA).  HEK-293 and SK-N-
SH cells were transfected with 0.4 µg and 0.2 µg cDNA per well, respectively.  
Subsequent uptake or kinetics assays were performed 24 hours post-
transfection.  Unless noted otherwise, cells lines transiently expressing wild-type 
or mutated DAT cDNA were used for all experiments.  
 
2.1.3 Stable Expression of Wild-type DAT 
To generate monoclonal cell lines stably expressing wild-type DAT (DAT 
HEK cells), 70% confluent HEK-293 cells were transfected with 10 µg of eGFP 
wild-type human DAT cDNA for 2 hours using Lipofectamine/PLUS reagents 
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(Invitrogen).  The transfected cells were split at 48 hours post-transfection into 
100 mm cell culture dishes at a 1:10 dilution. G418 (1 mg/ml) (Sigma-Aldrich) 
antibiotic was added to the culture media 24 hours post-split for selection.  After 
seven days of selection, G418-resistant colonies were plucked with cloning disks 
(Bel-Art, Pequannock, NJ), and the individual colonies were transferred into 24 
well plates containing growth media. The colonies grew to 80% confluence, and 
those fluorescing eGFP were transferred to a larger culture flask for expansion.  
HEK-293 cells stably expressing eGFP wild-type DAT were maintained in growth 
media supplemented with 0.3 mg/ml G418 antibiotic.  
 
2.1.4 [3H] Dopamine uptake assays 
HEK-293 or SK-N-SH cells were seeded in twelve well plates and 
transiently transfected with wild-type or G130T DAT as described above.  Cells 
were then preincubated in serum-free media with or without ethanol (25, 50,100 
mM) for 60 or 120min (3 wells per a condition). The ethanol pre-treatment media 
was quickly removed, and replaced with either the cell’s respected growth media 
or KRH buffer (120 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 
mM KH2PO4, 10 mM HEPES, pH 7.4) containing 100 nM [3H]DA and 
corresponding ethanol treatment (25, 50, 100 mM) for a 5 min incubation at 37°C 
to initiate [3H]DA uptake.  For the 5 min time point, cells were exposed to ethanol 
only during the uptake assay.  Control cells, expressing wild-type or G130T DAT, 
were incubated in growth media containing 100 nM [3H]DA without ethanol.  
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Uptake was terminated by quickly removing media, and washing the cells three 
times in 1 ml of ice-cold KRH buffer.  Cells were then lysed with 500 µl of 1% 
sodium dodecyl sulfate (SDS) for 15 min at room temperature with gentle 
shaking.  The whole-cell lysate was used to measure [3H] DA uptake and protein 
concentration. Accumulation of [3H]DA in the wild-type DAT or G130T DAT 
expressing cells was quantified in a liquid scintillation counter.  Protein 
concentration (DC protein assay, Bio-Rad, Hercules, CA) was used to normalize 
the uptake assays, and nonspecific [3H]DA uptake was determined by measuring 
uptake in the presence of the DAT inhibitor, cocaine (100 µM) (Sigma-Aldrich).   
 
2.1.5 Kinetics assay 
To determine the kinetics parameters (Km and Vmax) of DAT-mediated 
[3H]DA uptake, HEK-293 cells were seeded in twelve-well plates (3 wells per 
condition), and transfected with wild-type DAT, as described above.   Cells were 
treated with ethanol under maximal uptake conditions, determined by the dose 
and time dependent experiments (100 mM ethanol in serum-free media for 60 
min). Kinetics of DAT-mediated dopamine uptake was evaluated by measuring 
uptake of [3H]DA (100 nM) in the presence of increasing non-radioactive DA 





2.1.6 Cell surface biotinylation 
Stably expressing DAT HEK cells were grown to 85-90% confluence in 
two T-150 culture flasks.  The cells were washed twice with room temperature 
phosphate buffer saline (PBS), pH 7.4 (Gibco), and incubated at 37°C for 60 min 
with 10 ml of KRH buffer in the presence or absence of 100 mM ethanol.  Cells 
were quickly washed twice with ice-cold PBS supplemented with 0.1 mM CaCl2 
and 1 mM MgCl2 (PBS2+), and incubated with 10 ml of 1.0 mg/ml 
sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate (EZ-link Sulfo-NHS-
SS-Biotin) (Pierce, Rockford, IL) for 1h at 4°C.  Excess biotin was quenched with 
two washes of ice-cold PBS2+ supplemented with 100 mM glycine, followed by 
two additional washes with ice-cold PBS2+.  Biotinylated cells were scraped into 
the final wash, collected by centrifugation at 1000xg for 5min, broken by 
ultrasonic sonication, and lysed in 0.5 ml of radioimmunoprecipitation assay 
buffer (150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1.0% Triton X-100, 1% 
deoxycholate, 5 mM EDTA, and protease inhibitor cocktail) for 30 min on ice with 
intermittent agitation.  The lysate was cleared of insoluble material by 
centrifugation at 10,000xg for 10min at 4°C, and 1:10 aliquot of the lysate was 
reserved to be analyzed later as total protein sample (total).  The remainder of 
the cleared lysate was rocked overnight with 500 µl of UltraLink Immobilized 
NeutrAvidin Protein Beads (Pierce) at 4°C to separate biotinylated (cell surface) 
from non-biotinylated (intracellular) proteins via affinity chromatography.  
Unbound proteins were removed by 1000xg centrifugation at 4°C for 2 min.  After 
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three washes with PBS, pH 7.4, the beads were incubated with 2x Laemmli 
buffer for 1 hr at room temperature while rocking to elute biotinylated (cell 
surface) proteins bound to NeutrAvidin beads. The protein concentration of the 
lysates was determined using DC  Protein Assay kit (Bio-Rad, Hercules, CA), 
and an equal amount of protein was separated by SDS-PAGE in a 7.5% Tris-HCl 
Ready gel (Bio-Rad). After the proteins were transferred to polyvinylidene 
difluoride (PVDF) membrane, the blots were blocked overnight at 4°C in Tris-
buffered saline (TBS-T) (10 mM Tris-Cl, pH 8; 150 mM NaCl; 0.01%Tween-20 ) 
containing 5% non-fat dried milk (Bio-Rad). DAT was detected with a rat 
monoclonal antibody specific for the N-terminus of DAT (MAB 369; Millipore-
Chemicon, Billeria, MA) for 2 hr at room temperature while rocking in TBS-T 
containing 1% non-fat dried milk and 1% BSA.  After three 10 min washes in 
TBS-T, blots were visualized using a horseradish peroxidase conjugated rat 
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) with enhanced 
chemiluminescence solution (Perkin Elmer, Boston, MA).  Immunoreactivity was 
detected using Kodak Image Station 2000 mm, and band intensities were 
quantified with NIH Image J software.  Blots were stripped and reprobed with 
antibodies against an intracellular marker, calnexin, an endoplasmic reticulum-
resident protein.  The absence of calnexin in the biotinylated protein sample 
indicates the integrity of the cell membrane was maintained during the 
biotinylation process, and only cell surface proteins were labeled.      
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2.1.7 Data Analysis 
Specific uptake was calculated as the difference between total and non-
specific uptake.  Maximal ethanol potentiation was determined by pooling 
maximum [3H]DA uptake data from each ethanol dose / time dependence 
experiments and calculating the mean for each cell type.  Kinetic parameters (Km 
and Vmax) were determined by non-linear regression line analysis using 
Graphpad Prism, version 4.0 software.  Ethanol-induced changes in DAT cell 
surface density was determined by quantifying the optical densities (OD) from the 
Western analysis of cell surface and total populations of the transporter.  The 
relative amount of surface DAT was calculated by normalizing surface population 
OD to their respective total population OD of the transporter to obtain a ratio of 
surface expression.  The ratio of surface expression in the ethanol treated 
sample was then normalized to the untreated ratio. The student’s T test was 
used to compare ethanol treated samples to untreated controls, and one-way 
ANOVA with post-hoc analysis for dose and time comparisons.     
 
2.2 Methods for Chapter Four (Specific Aim Two) 
 
2.2.1 DNA constructs 
cDNA encoding human DAT was obtained as previously described (Maiya 
et al. 2002).  Mutant transporters were constructed from DAT cDNA subcloned 
into a pBK-CMV vector (Stratagene). Mutagenesis was performed using the 
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Quick Change site-directed mutagenesis kit (Stratagene) to replace glycine 130 
with threonine (G130T).  Both DAT and G130T DAT cDNA were subcloned into 
the mammalian expression vector pEGFP-C1 as described previously (Riherd et 
al. 2008).         
 
2.2.2 Cell culture and stable transfections 
Human embryonic kidney cells (HEK-293) (ATCC) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum and 0.1% penicillin / streptomycin.  HEK-293 cells were stably transfected 
with DAT or G130T DAT cDNA as previously described (Riherd et al. 2008). 
HEK-293 cells stably expressing DAT (DAT HEK cells) or G130T DAT (G130T 
DAT HEK cells) were cultured and maintained as previously described (Riherd et 
al. 2008). The constructs contained an enhanced green fluorescent protein 
(eGFP) tag to visually confirm transporter expression. 
 
2.2.3 [3H]DA Uptake Assays 
Stably expressing DAT or G130T DAT HEK cells were seeded on poly-D-
lysine coated 12-well plates at a density of 0.5 x 105 per well. Cells were 
incubated at 25°C in serum-free DMEM in the absence or presence of ethanol 
(10, 50, 100 mM) for 5, 30 or 60 min (three wells per condition).  Uptake was 
initiated by adding 20 nM [3H]DA during the final 3 min of the incubation time.  
Non-specific [3H]DA uptake was determined using 100 µM PPP (S-(-)-3-(3-
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hydroxyphenyl)N-propylpiperidinine hydrochloride; Sigma).  Cells were washed 
three times in ice-cold Krebs-Ringer-HEPES buffer (120 mM NaCl, 4.7 mM KCL, 
2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 10 mM HEPES, pH 7.4) and 
lysed in 500 µl of 1% sodium dodecyl sulfate (SDS) for 15 min at room 
temperature with gentle shaking.  Accumulation of [3H]DA in the cells was 
quantified using liquid scintillation spectrometry (Beckman LS 6500; Beckman 
Coulter). Statistical significance was determined in Prism 4 by unpaired, two-
tailed t test (basal uptake comparisons and individual time point comparisons to 
controls) and one-way ANOVA.  Concentration- and time-dependent effects of 
ethanol on [3H]DA uptake were calculated by post-hoc analysis for linear trend. 
 
2.2.4 Biotinylation 
To assess the effects of ethanol on DAT surface localization, DAT or 
G130T DAT HEK cells were seeded on tissue-culture treated 100 mm plates and 
grown to 80-90% confluence. Cells were incubated for 1 hr at 37°C in serum-free 
DMEM in the absence or presence of 100 mM ethanol.  Surface proteins were 
biotinylated with 1 mg/ml biotin (sulfo-NHS-SS-biotin; Pierce) in PBS2+ for 30 min 
at 4°C as described above (Riherd et al. 2008).  Biotinylated and non-biotinylated 
proteins were separated separated by incubation overnight at 4°C with pre-
washed streptavidin M-280 Dynabeads (Invitrogen) on a rotating platform. Beads 
were washed three times with ice-cold PBS2+ containing protease inhibitor 
cocktail.  Biotinylated proteins were eluted using 2x Laemmli buffer for 1 hr at 
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room temperature on a rotating platform.  Total lysate and biotinylated proteins 
were analyzed with SDS-PAGE, immunoblotting and densiometry as previously 
described (Riherd et al. 2008).  Blots were probed using a rat monoclonal 
antibody against the N-terminus of human DAT (MAB369, Chemicon) and a 
mouse monoclonal antibody against the endogenously recycled protein, human 
transferrin receptor (TfR) (13-6800, Zymed).  To ensure the integrity of the 
plasma membrane was maintained during biotinylation, blots were also re-probed 
with a mouse monoclonal antibody against an intracellular marker, (CAL) 
calnexin (MAB3126; Chemicon), an endoplasmic reticulum protein. 
 
2.2.5 Endosomal recycling pool measurment 
To measure recycling pool size, cells were exposed to 1 mg/ml biotin in 
the absence or presence of 100 mM ethanol under trafficking permissive 
temperatures (37°C) for 30-90 min.  Cells were solubilized in RIPA containing 
protease inhibitor cocktail.  Biotinylated and non-biotinylated proteins were 
separated, and analyzed with immunoblotting as describe above.  
 
2.2.6 Insertion Assays 
Delivery of DAT to the plasma membrane was measured using a modified 
surface biotinylation assay at trafficking-permissive temperatures.  First, surface 
proteins were biotinylated at 4°C (trafficking-restrictive) as described above.  
Excess biotin was removed, and cells were washed twice with ice-cold PBS2+.  
 47 
To initiate protein trafficking, cells were quickly washed with pre-warmed PBS2+ 
and incubated at 25°C in PBS2+ containing 1 mg/ml biotin ± ethanol (100 mM) for 
the desired time (t)  (2, 5, 15 or 30 min). Additional biotinylated cells were kept in 
parallel at 4°C to measure basal DAT surface levels at t=0.  The biotin reaction 
was quenched by two washes with ice-cold 100 mM glycine followed by two 
washes with ice-cold PBS2+.  Biotinylated and total lysate proteins were 
separated and analyzed by immunoblotting as described above.  Insertion rate 
was calculated as described previously (Wang and Quick 2005). Briefly, 
biotinylated transporter was normalized to the respective total cellular DAT for 
each time point. Newly inserted transporters (Tt ) were then measured as the 
increase in biotinylated DAT at each time point over basal DAT surface levels (T0 
), and plotted over time.  The rate was determined by fitting the time course of 
biotinylation to a single exponential equation to solve for τ: Tt =T0 + A[1-e (-t/τ)] 
where Tt = biotinylated DAT at time (t), T0 =basal DAT surface levels, A= Tt – T0, 
τ=time constant; Rate=1/τ (min-1).   
 
2.2.7 Internalization assays 
Intracellular accumulation of the transporter and relative internalization 
rates were measured using a reversible biotinylation assay.  DAT HEK cells were 
biotinylated at 4°C as described above, and the reaction was quenched with ice-
cold 100 mM glycine.  Cells were quickly washed with pre-warmed PBS2+ to 
initiate trafficking and incubated at 25°C in PBS2+ ± 100 mM ethanol for 2, 5, 15 
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or 30 min.  Trafficking was rapidly halted by washing cells twice with ice-cold NT 
buffer (150 mM NaCl, 1 mM EDTA, 0.2% bovine serum albumin, 20 mM Tris, pH 
8.6).  Biotin remaining on the cell surface was cleaved using freshly prepared 50 
mM TCEP (Tris(2-carboxyethyl)phophine hydrochloride; Pierce) in ice-cold NT 
buffer.  TCEP was applied for 20 min at 4°C, removed and replaced with fresh 
TCEP for an additional 20 min incubation at 4°C.  Biotinylated cells were kept in 
parallel at 4°C to measure total surface DAT (t=0).  The stripping efficiency of the 
reducing reagent was determined by washing biotinylated cells with TCEP 
without allowing trafficking at 25°C.  Cells were lysed, and biotinylated proteins 
were separated and collected using streptavidin Dynabeads as described above.  
The biotinylated fraction represented proteins internalized during trafficking.  The 
total number of internalized transporter was calculated as the percent of 
biotinylated DAT (Tt) compared to total surface DAT (TS; T0).  The rate of 
internalization was determined using the same equation used to estimate 
insertion rate. 
 
2.3 Methods for Chapter Five (Specific Aim Three) 
 
2.3.1 Cell culture and stable transfections 
Wild-type DAT and the IGLF mutant DAT (DAT residues replaced with 
cooresponding NET residues in the first intracellular loop, I137F, G130T, L138F, 
F123Y)  (Maiya et al. 2002) were constructed from wild-type human DAT cDNA 
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subcloned in a pBK-CMV vector (Stratagene, La Jolla, CA) using the 
QuikChange site-directed mutagenesis kit (Stratagene), as described above.  
Mutagenesis was verified by sequence analysis performed by the DNA 
Sequencing Core Facility at The University of Texas at Austin. 
Monoclonal cell lines stably expressing wild-type DAT or IGLF mutant 
DAT (DAT HEK and IGLF HEK cells, respectively) were generated, as described 
above.  Briefly,  70% confluent HEK-293 cells were transfected with 10 µg of 
eGFP wild-type human DAT or eGFP IGLF DAT cDNA for 2 hours using 
Lipofectamine/PLUS reagents (Invitrogen).  Stably expressing DAT or IGLF HEK 
cell colonies were selected with G418 antibiotic, plucked with cloning discs, and 
transferred to larger culture flasks for expansion.  Stably expressing cell lines 
were maintained in growth media supplemented with 0.3 mg/ml G418.  
 
2.3.2 [3H] Dopamine uptake assays 
Stably expressing DAT or IGLF DAT HEK cells were seeded on poly-D-
lysine coated 12-well plates at a density of 0.5 x 105 per well. [3H]DA uptake 
assays were prefomed as described above.  Briefly, cells were incubated at 25°C 
in serum-free DMEM for 60min. Uptake was initiated by adding 20 nM [3H]DA 
during the final 3 min of the incubation time.  Non-specific [3H]DA uptake was 
determined using 100 µM PPP.  Cells were washed three times in ice-cold 
Krebs-Ringer-HEPES buffer, and lysed in 500 µl of 1% sodium dodecyl sulfate 
(SDS) for 15 min at room temperature with gentle shaking.  Accumulation of 
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[3H]DA in the cells was quantified using liquid scintillation spectrometry (Beckman 
LS 6500; Beckman Coulter). Statistical significance was determined in Prism 4 
by unpaired, two-tailed t test. 
 
2.3.3 Cell surface biotinylation 
Cell surface levels of DAT or IGLF DAT was analyzed using the 
bioinylation method described above.  Briefly, cells were seeded in T-150 flasks, 
and grown to 80-90% confluence. Cells were incubated for 1 hr at 37°C in serum-
free DMEM.  The cells were washed twice with ice-cold PBS2+, and surface 
proteins were biotinylated with 1 mg/ml biotin in PBS2+ for 30 min at 4°C as 
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3.1 Introduction 
Activation of the dopaminergic system in the mesolimbic areas of the brain 
controls a variety of physiological functions, including locomotion, emotion, and 
reward and reinforcement learning. The duration and strength of dopamine (DA) 
neurotransmission is dependent on the concentration of the neurotransmitter in 
the synaptic cleft.  Re-uptake by the plasma membrane dopamine transporter 
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(DAT), located on the peri-synaptic terminal of dopaminergic neurons, 
predominately terminates dopaminergic neurotransmission and maintains 
homeostatic transmitter levels (Giros et al. 1991, Melikian and Buckley 1999, 
Gainetdinov and Caron 2003).  DAT is a member of the Na+/Cl- family of 
neurotransmitter transporters that includes glycine, norepinephrine (NET), 
serotonin (SERT), and γ-aminobutyric acid (GAT1) transporters (Nelson 1998, 
Rudnick 1998).  The transporters have similar topological arrangements and 
serve to terminate neurotransmission by removing transmitter from the 
extracellular space (Rudnick 1998).   
Neurotransmitter transporters undergo rapid and dynamic trafficking to 
and from the cell surface in order to regulate neurotransmission. (Zhang et al. 
1997, Melikian and Buckley 1999, Chi and Reith 2003, Li et al. 2004). The 
functional regulation of DAT, via alterations in the cell surface expression of the 
transporter, can occur through signaling cascades and exposure to DAT 
substrates.  Phorbol ester activation of protein kinase C, tyrosine kinase 
inhibition, and N-glycosylation prevention decreases the transporter activity by 
down-regulating DAT surface expression (Vaughan et al. 1997, Zhang et al. 
1997, Melikian and Buckley 1999, Li et al. 2004, Miranda et al. 2005, Hoover et 
al. 2007). When expressed in Xenopus Laevis oocytes, stimulation of the D2 
receptor induces a voltage-independent upregulation of DAT activity and [3H]WIN 
35428 surface binding, dependent on G(i/o) protein activation (Mayfield and 
Zahniser 2001). Similar studies in midbrain primary culture and human 
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embryonic kidney cells (HEK-293) reveal D2 receptor stimulation increases DAT 
activity and surface expression via direct protein-protein interaction and ERK 1/2 
pathways (Bolan et al. 2007, Lee et al. 2007).  Stimulation of D3 receptors 
expressed in HEK-293 cells also upregulates DAT activity and surface 
expression through MAPK and PI3K pathways (Zapata et al. 2007). Exposure to 
DAT substrates, inhibitors and other pharmacological reagents, such as 
psychostimulants can also alter DAT surface expression levels altering 
dopaminergic signaling in the brain.   
   Ethanol and psychostimulants such as cocaine and amphetamine induces 
cellular and molecular maladaptive changes in dopaminergic reward pathways, 
including alterations in DA release and/or DAT mediated DA uptake (Di Chiara 
and Imperato 1988, Koob and Weiss 1992, Zahniser and Doolen 2001, Zahniser 
and Sorkin 2004, Jayanthi and Ramamoorthy 2005, Hyman et al. 2006).  Acute 
or chronic (or both) exposure to cocaine, d-amphetamine, and ethanol has been 
reported to alter DAT cell surface densities (Mayfield et al. 2001, Daws et al. 
2002, Chi and Reith 2003, Gulley and Zahniser 2003, Zahniser and Sorkin 2004, 
Jayanthi and Ramamoorthy 2005, Johnson et al. 2005, Kahlig et al. 2006, Chen 
and Reith 2007).   Cocaine rapidly increases DAT surface expression in 
mammalian cells and synaptosomes from rat striatum (Daws et al. 2002, Little et 
al. 2002, Chi and Reith 2003, Chen and Reith 2007), and competitively inhibits 
DAT-mediated DA uptake (Ritz et al. 1988).  Other studies have shown chronic 
cocaine administration does not change the number of DAT binding sites, but 
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causes a dose-dependent reduction in DAT mRNA expression (Letchworth et al. 
1997).  Amphetamines also increase dopaminergic signal strength by reducing 
DAT-mediated DA uptake.  D-amphetamine acts as a substrate for DAT and the 
vesicle transporter, VMAT2 causing competitive inhibition of DA binding, and 
reverse DA transport (Sulzer et al. 1993, Sulzer et al. 1995, Saunders et al. 
2000, Johnson et al. 2005, Kahlig et al. 2006). 
It is generally accepted that ethanol elevates synaptic DA concentrations 
by activating mesolimbic dopaminergic neurons (Imperato and Di Chiara 1986, 
Yoshimoto et al. 1992, Brodie and Appel 1998).  However, ethanol’s action on 
DAT is currently under debate.  In vitro studies suggest ethanol has a 
potentiating effect on the transporter.  After a 24 hour exposure, ethanol and 
cocaine increase DAT-mediated DA uptake both individually and combined in 
neuronal, but not non-neuronal, cell lines expressing the transporter (Ho and 
Segre 2001).  These studies suggest ethanol and cocaine alters DAT function 
through a common neural pathway.  However, electrophysiological and 
biochemical studies in transporter-expressing Xenopus laevis oocytes have also 
shown ethanol exposure potentiates DAT function and increases [3H]WIN 35428 
surface binding (Mayfield et al. 2001, Maiya et al. 2002).  Two amino acids in the 
first intracellular loop of DAT, glycine 130 and isoleucine 137, mediate ethanol 
sensitivity of the transporter (Maiya et al. 2002).  
In vivo studies examining the effects of chronic ethanol exposure on DAT 
suggest ethanol increases the number of DAT binding sites in alcohol-preferring 
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vervet monkeys (Mash et al. 1996), the striatum of violent alcoholics (Tiihonen et 
al. 1995), and in specific brain regions of Wistar-Kyoto rats. (Jiao et al. 2006).  
Chronic in vivo ethanol exposure has also been reported to potentiate DAT-
mediated dopamine uptake    (Carroll et al. 2006, Budygin et al. 2007).  However, 
the acute action of ethanol in vivo is less clear.  Electrochemical studies in mice 
and rats suggest ethanol has no effect on the transporter  (Budygin et al. 2001, 
Budygin et al. 2005, Jones et al. 2006, Mathews et al. 2006). However, other 
electrochemical studies have shown acute ethanol either increases (Wang et al. 
1997, Sabeti et al. 2003) or decreases dopamine uptake (Robinson et al. 2005).   
The present studies aimed to investigate the hypothesis that short-term (≤ 
2 hours) ethanol exposure alters DAT trafficking and increases cell surface 
distribution of DAT, potentiating transporter-mediated DA uptake in heterologous 
expression systems.  We chose a neuronal mammalian cell line, 
catecholaminergic SK-N-SH neuroblastoma cells (Richards and Sadee 1986, Liu 
et al. 2001), and non-neuronal, HEK-293 cells, to express the transporter. 
Biochemical methods were used to characterize the effects of ethanol on 
transporter function and trafficking. We found ethanol potentiates DAT-mediated 
DA uptake in neuronal and non-neuronal cells expressing the transporter. This 
potentiation appears to be associated with an increase in expression of the 
transporter on the cell surface.  Our results suggest ethanol has a direct 
mechanistic action in modulating DAT functional regulation in mammalian cell 
systems.  These findings demonstrate ethanol’s potentiating effect on the 
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transporter is consistent across multiple expression systems, and furthers our 
understanding of the molecular mechanisms of ethanol’s action in mammalian 
systems.   
 
3.2 Ethanol effects on dopamine uptake in transient DAT expressing SK-N-
SH and HEK-293 cells 
We examined ethanol actions on DAT function in SK-N-SH and HEK-293 
cells expressing the transporter by [3H]DA uptake assays.   SK-N-SH and/or 
HEK-293 cells expressing wild-type or ethanol insensitive mutant (G130T) were 
pre-treated with ethanol (25, 50, 100 mM) for 0, 60 or 120 min, followed by an 
incubation in 100 nM [3H]DA and corresponding ethanol treatment for 5 min at 
37°C.  Dopamine uptake was measured as the accumulation of [3H]DA into DAT 
expressing cells. The 5 min time point includes cells exposed to ethanol only 
during the course of the uptake assay.  Baseline dopamine uptake (untreated 
control cells) by SK-N-SH and HEK-293 cells expressing G130T DAT was not 
significantly different from the baseline uptake in cells expressing wild-type DAT 
(data not shown).  Ethanol enhanced dopamine uptake in wild-type expressing 
SK-N-SH cells in a dose, but not time, dependent manner (Figure 3.1.A).  The 
dose-response curve differed slightly from assay to assay, but a clear dose 
response pattern was observed for each individual assay (representative assay, 
13, 27,and 30% potentiation for 25, 50, and 100 mM ethanol, respectively) 
(Figure 1A, inset).  In SK-N-SH cells expressing the G130T DAT mutant, dose 
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response patterns also differed between assays (Figure 3.1.B); however, there 
was no dose or time response relationship observed in individual assays 
(representative assay, 27,14,and 18% potentiation for 25, 50, 100 mM ethanol, 
respectively) (Figure 3.1.B, inset).   
 
 
Maximal ethanol effects (see methods) on transfected HEK-293 cells were 
similar to those seen in transfected SK-N-SH cells (Figure 3.2).  For SK-N-SH 
Figure 3.1: Dose and time 
dependent effects of ethanol pre-
treatment on [3H]DA (100 nM) 
uptake in DAT expressing SK-N-
SH cells.. A. Wild-type DAT-
mediated [3H]DA uptake. Ethanol 
significantly enhanced uptake 
compared to untreated controls 
for all pretreatment times, but not 
in a time dependent manner. 
(inset) Dose response relationship 
was variable between assays, but 
evident in individual assays. 
(representative 60 min ethanol 
pretreatment assay shown). B. 
G130T DAT-mediated [3H]DA 
uptake. Ethanol significantly 
enhanced uptake compared to 
untreated controls for all pre-
treatment times, but not in a time 
dependent manner. (inset) Dose 
response relationship was 
variable between assays, and in 
individual assays (representative 
60min ethanol pre-incubation 
assay shown). Data are 
expressed as means ± SEM of 
four experiments. *p < 0.01 
compared with untreated control 
(one-way ANOVA for dose and 
time comparison tests). 
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and HEK-293 cells expressing wild-type DAT, ethanol maximally potentiated 
dopamine uptake at 51% and 55%, respectively.  In both cell lines expressing 
G130T DAT, ethanol significantly potentiated DAT-mediated [3H]DA 29% in SK-
N-S and 28% in HEK-293 (Figure 3.2).  However, ethanol-induced potentiation of 
uptake was significantly reduced in G130T DAT expressing SK-N-SH and HEK-
293 cells compared to cells expressing the wild-type transporter.  As seen 
previously, the untransfected SK-N-SH cells exhibited a low-level of transporter 
activity that could be blocked by 100 µM cocaine (Liu et al. 2001), and these cells 
were potentiated 13% by ethanol compared to untreated, untransfected SK-N-SH 







Figure 3.2: Maximum ethanol potentiation (see 
methods) from pooled [3H]DA uptake data in 
SK-N-SH and HEK-293 cells expressing wild-
type or G130T mutant DAT. Control cells, 
expressing wild-type or G130T DAT, were 
incubated in growth media with 100 nM [3H]DA 
without ethanol. Ethanol significantly 
potentiated transporter-mediated [3H]DA uptake 
compare to untreated controls in SK-N-SH cells 
expressing wild-type DAT or G130T DAT 51% 
AND 29%,respectively. Potentiation was 
significantly reduced in SK-N-SH cells 
expressing the G130Tmutant compared to wild-
type DAT expressing cells. Ethanol potentiated 
transporter-mediated [3H]DA uptake in HEK-
293 cells expressing wild-type DAT or G130 
DAT 55% and 28%,respectively. Potentiation 
was significantly reduced in HEK-293 cells 
expressing the G130Tmutant compared to wild-
type DAT expressing cells. Data are expressed 
as mean ± SEM of maximal uptake values from 
three experiments. *p < 0.05 compared with 
untreated control.**p<0.05 compared with wild-






3.3   Ethanol action on dopamine uptake kinetics  
Kinetics parameters (Vmax  and Km) of DAT-mediated [3H]DA uptake were 
determined to further evaluate the mechanistic action of ethanol on the 
transporter.  Cells were exposed to ethanol under maximal uptake conditions 
(100 mM ethanol for 60 min) determined by the dose / time dependent uptake 
assays described above.  Ethanol enhanced maximal dopamine uptake velocity 
(Vmax) 30-35% while the affinity for dopamine (KM) remained unchanged (Figure 






Figure 3.3: Ethanol pre-treatment (100 mM; 60 min) increased dopamine uptake 
velocity. Uptake of [3H]DA (10 nM-10 µM) was measured after a 60 min exposure to 
either KRH (control; fille circles) or ethanol (100 mM; open circles) in DAT expressing 
HEK-293 cells. Vmax (control 78.2 pmol/min/well; ethanol 107.9 pmol/min/well) and 
Km (control 1.06 µM; ethanol 1.12 µM) parameter estimates were obtained from the 
nonlinear regression curve fits. The graph is representative of four experiments. 
Each data point represents an average of three wells ± SEM. 
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3.4   Ethanol-induced changes of DAT cell surface localization 
To investigate if the ethanol-induced increase in dopamine uptake (Figures 
3.1 and 3.2) in DAT expressing mammalian cells was due to an increase in 
transporter expression on the cell surface, DAT surface density was examined by 
cell-surface biotinylation assays.  Stably transfected HEK-293 cells from the 
same monoclonal populations were used in all biotinylation experiments to 
increase immunoblot signal intensity and reduce variance between experiments.  
HEK-293 cells adhere strongly to the surface of the flasks, reducing the loss of 
cells during the multiple washes of these biochemical experiments.  Expression 
of total and cell surface population of wild-type DAT was determined in DAT HEK 
cells incubated in the presence or absence of ethanol (100 mM) for 1hr at 37°C 
(Figure 3.4.A). Total wild-type DAT was detected at ~55-125 kDa when assessed 
by anti-DAT (MAB 369; Chemicon).  The presence of the eGFP tag on the N-
terminal tail of the transporter increased the size  ~25 kDa from the expected size 
of DAT (~55-90 kDa).  The lower bands (~55-90 kDa) reflect lysosomal-degraded 
and unglycosylated DAT.  The upper bands (~90-125 kDa ) are glycosylated 
forms of the transporter, expected at the cell surface or in recycling pools of DAT.  
Ethanol (100 mM) had no effect on the total population of the transporter in cells; 
however, ethanol treatment significantly increased the surface density of DAT 
(Figure 3.4.B) by 40 - 50% (Figure 3.4B, inset).  Ethanol had no effect on the 
expression of the intracellular endogenous control protein, calnexin (Figure 
3.4.A).  Less than 2% of calnexin was biotinylated (data not shown), indicating 
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Figure 3.4: Ethanol increases surface density of DAT. Cells were incubated in KRH 
buffer in the absence or presence of 100 mM ethanol for 1h at 37°C. A. Representative 
immunoblots of DAT and calnexin in biotinylated DAT HEK cell lysate from four 
experiments. Shown are the total extracts (total DAT 55-125 kDa) and biotinylated 
extracts (cell surface DAT 90-125 kDa) from DAT HEK cells with indicated treatments.  
Blots were stripped and reprobed with the antibody for calnexin. B. Mean optical 
density (O.D.) of total DAT in ethanol-treated (empty bars) DAT HEK cells did not 
significantly change compared to total DAT in untreated cells (filled bars), while the cell 
surface DAT O.D. was significantly increased in ethanol treated cells. **p <0.01 
compared to untreated surface DAT O.D. (Student's t test). (inset) Quantification of the 
percent change in cell surface DAT populations between ethanol treated and untreated 
cells. Ethanol significantly increases surface DAT populations 40-50% (expressed as a 
percentage relative to the total amount of DAT in the respective lysate (untreated or 
ethanol-treated) and normalized to untreated surface DAT). Data are expressed as 
normalized values ± SEM of four experiments. *p < 0.05 compared with untreated 
surface DAT population (Student’s t test). 
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3.5  Discussion 
The goal of this study was to determine the direct action of ethanol on DAT 
functional regulation in mammalian cell expression systems.  We found a short-
term ethanol exposure potentiates dopamine uptake in both mammalian neuronal 
(SK-N-SH) and non-neuronal (HEK-293) wild-type DAT expressing cells.  This 
potentiation was significantly reduced in cells expressing the ethanol insensitive 
mutant, G130T DAT.  Ethanol-induced enhancement of DAT activity was 
associated with an increase in transporter expression on the cell surface.  Our 
results in mammalian systems are in agreement with similar biochemical studies 
examining the effects of ethanol on DAT functional regulation in other in vitro 
systems (Mayfield et al. 2001, Maiya et al. 2002).  Ethanol alters the functional 
regulation of DAT across multiple expression systems, suggesting a direct 
mechanistic action of ethanol on the transporter trafficking system.   
The reward and reinforcing effects of ethanol are predominately mediated 
through the mesolimbic dopaminergic system (Di Chiara and Imperato 1988, 
Carboni et al. 2000, Engleman et al. 2000, Katner and Weiss 2001, Tang et al. 
2003b, Gonzales et al. 2004).  Maladaptive changes in various properties of the 
dopaminergic system, including regulation of neurotransmission, contribute to 
ethanol addiction (Gonzales et al. 2004). Mammalian cell lines serve as 
important model systems to study the molecular mechanisms of drug and alcohol 
action.  In this study, catecholaminergic SK-N-SH neuroblastoma and non-
neuronal HEK-293 cells served as our mammalian cell model systems.  Both cell 
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lines were transfected with human wild-type or ethanol-insensitive G130T DAT to 
detect the effects of short-term ethanol exposure on DAT function and cell 
surface expression. These studies allowed us to identify potential molecular 
mechanisms of ethanol action on the transporter.  
We found ethanol exposure potentiates dopamine uptake in 
neuroblastoma SK-N-SH and non-neuronal HEK-293 cells expressing wild-type 
DAT.  Ethanol increased DAT activity in a clear dose-dependent manner within 
each individual assay. The dose response relationship was more variable across 
assays.  This variation was likely due to differences in transfection efficiencies, 
growth rates, or passage number.   Previous studies examining the effects of a 
24 hour exposure to ethanol and cocaine (individually or combined) in neuronal 
and non-neuronal cell lines resulted in an increase in DAT-mediated DA uptake 
only in neuronal cell lines (Ho and Segre 2001).  Their results suggest ethanol 
and cocaine act on DAT through common neural-specific pathways to alter 
transporter function.  We found ethanol alters DAT function in both non-neuronal 
and neuronal cell lines.  This contradiction could be due the differences in 
ethanol exposure time and/or cell type.  Our results suggest ethanol may have a 
direct mechanistic action on the transporter trafficking system.  The SK-N-SH cell 
line used in these studies endogenously express NET and DAT.  These 
transporters are responsible for a low level of uptake, which was not blocked 
during these assays.  However, this endogenous uptake is negligible compared 
to the uptake by the wild-type or G130T DAT overexpressed in these cells, thus 
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any contribution of endogenous transporters to our reported effects is minimal.  
Our results demonstrating the enhancement of DAT activity by ethanol are 
consistent with previous electrochemical, chronoamperometry, and biochemical 
experiments in rats (Wang et al. 1997, Sabeti et al. 2003), and Xenopus oocytes 
(Mayfield et al. 2001, Maiya et al. 2002).  
Chimera and site-directed mutagenesis studies in the Xenopus oocyte 
expression system identified the site of ethanol action at the first intracellular loop 
between transmembrane domains two and three of DAT.  Specifically, a mutation 
of glycine 130 for threonine, a non-conservative amino acid change, eliminated 
the potentiating effects of ethanol on transporter action and cell surface binding 
in a Xenopus oocyte expression system (Maiya et al. 2002).  As seen in oocytes, 
basal [3H]DA uptake (0 mM ethanol) in SK-N-SH and HEK-293 cells expressing 
G130T DAT is similar to wild-type DAT.  However, in the mammalian cell models 
the mutation reduced, but did not eliminate ethanol sensitivity.   While the G130T 
mutant demonstrated a significant potentiation of function after ethanol exposure, 
potentiation was also significantly reduced by half compared to wild-type DAT 
expressing cells.  This ethanol-induced increase in G130T DAT activity was not 
dose-dependent.  The lack of a dose-response effect is not due to variance in 
transfection efficiency, growth rates, or passage number, because none of the 
individual assays demonstrated a dose-response pattern.  It is more likely due to 
the reduced sensitivity of the DAT mutant to ethanol. Alternatively, ethanol could 
be acting as an allosteric modulator of DAT, as seen with the GABA(A) receptor .  
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This would suggest the G130T mutation disrupts a critical allosteric modulation 
site for ethanol.  However, the potentiation of DAT function is associated with an 
ethanol-induced increase in surface expression of the transporter, as seen in the 
biochemical studies described above (Figure 3.4) and in oocytes (Mayfield et al. 
2001, Maiya et al. 2002).  We hypothesize the G130T mutation is disrupting a 
protein-protein interaction site critical for ethanol-regulated trafficking of DAT to 
the cell surface.  The elimination of ethanol sensitivity in G130T DAT expressing 
oocytes was attributed to a lack of change in cell surface distribution of the 
transporters (Maiya et al. 2002). The differences in ethanol potentiation between 
oocytes and mammalian cells are is most likely due to differences in trafficking 
mechanisms and/or cellular machinery in the model systems.  Studies are in 
progress to examine the differences in ethanol-induced trafficking of G130T 
versus wild-type DAT in mammalian cell expression systems. 
Trafficking and alterations in surface distribution of DAT is the 
predominant mechanism to rapidly regulate transporter function (Jayanthi and 
Ramamoorthy 2005, Maiya et al. , Torres 2006).  Psychostimulants such as 
cocaine and amphetamine have been shown to modulate DAT activity by 
redistributing the transporter to the cell surface.  Our kinetics data demonstrated 
DAT activity was potentiated by ethanol (increased Vmax) with no change in 
transporter binding affinity (Km).  The potentiation of uptake velocity parallels an 
increase number of transporters on the cell surface in DAT HEK cells.  While 
stably expressing DAT HEK-293 cells have been reported to have higher levels 
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of [3H]DA uptake compared to transiently expressing cells (Chen and Reith 
2007), our results are in agreement with other in vitro studies using DAT 
expressing Xenopus oocytes where potentiation of DAT activity by ethanol also 
correlated with an increase in [3H]WIN 35428 surface binding (Mayfield et al. 
2001).  In vivo, ethanol has been reported to differentially modulate the 
expression of a variety of proteins in mesolimbic areas of the brain (Bell et al. 
2006), including DAT (Tiihonen et al. 1995, Mash et al. 1996, Jiao et al. 2006).   
Abstinent alcohol-preferring vervet monkeys have an increase number of cell 
surface DAT, and chronic alcohol consumption down-regulates surface DAT 
expression (Mash et al. 1996).   However, chronic ethanol has also recently been 
shown to increase DAT binding in specific brain regions of Wistar-Kyoto rats, 
including areas of the mesolimbic system involved in addiction (Jiao et al. 2006), 
while differential expression of surface DAT has been seen in violent versus non-
violent alcoholics (Tiihonen et al. 1995).  These changes could reflect ethanol-
induced neuroadaptations in the brain, but further research is needed to compare 
expression differences between various brain regions, drinking models, and 
model systems.   
Ethanol-mediated increases in DAT activity and cell surface expression 
after a short-term exposure, could represent a mechanism that underlies an 
acute functional tolerance to ethanol (Mayfield et al. 2001). Another amine 
transporter of the Na+/Cl- family, GAT1, has been shown to have an acute 
tolerance to ethanol (Byas-Smith et al. 2004).  Although GAT1 does not directly 
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interact with ethanol, transporter activity increased in response to acute ethanol 
exposure.  Interestingly, the DAT inhibitor, GBR 12909 and ethanol cross-
sensitize in DBA/2J mice (Broadbent et al. 2005).  These experiments suggest 
DAT inhibition unmasks increased basal levels of dopamine due to ethanol 
sensitization, which is normally compensated for by DAT uptake activity.  
It is generally accepted ethanol exposure increases dopamine release in 
the mesolimbic areas of the brain (Yim and Gonzales 2000, Gonzales et al. 
2004).  However, ethanol action on DAT regulation is currently under debate.  In 
vivo, chronic ethanol exposure has been shown to increase DAT-mediated 
uptake (Carroll et al. 2006, Budygin et al. 2007), while acute ethanol has been 
reported to increase (Wang et al. 1997, Sabeti et al. 2003), decrease (Robinson 
et al. 2005) or have no effect on DAT activity (Budygin et al. 2001, Budygin et al. 
2005, Jones et al. 2006, Mathews et al. 2006).  Electrochemical studies using the 
‘no net flux’ microdialysis method suggested acute ethanol-induced increases in 
dopamine levels were not due to an inhibition in transporter function, but an 
increase in release (Yim and Gonzales 2000).  In vitro electrophysiological and 
biochemical experiments in a Xenopus oocyte model system, which measured 
DAT activity in a more direct manner, suggested ethanol exposure increases 
DAT-mediated uptake through a redistribution of transporter expressed on the 
cell surface (Mayfield et al. 2001, Maiya et al. 2002).  Many of the 
electrochemical studies described above indirectly examine transporter activity 
and regulation as a function of alterations in extracellular dopamine levels.  The 
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contradiction between findings could be contributed to inherent differences 
between model systems and/or techniques.  
In conclusion, we determined ethanol induced a potentiation of DAT 
activity in both DAT-expressing neuroblastoma SK-N-SH and non-neuronal HEK-
293 mammalian cells.  This potentiation appears to be associated with an 
increase in the number of transporters expressed on the cell surface. These 
findings are in agreement with similar biochemical experiments in other in vitro 
systems, suggesting ethanol may have a direct action on the transporter’s 
trafficking system thus modulating DAT functional regulation.  In this study, we 
established and characterized working mammalian cell lines for future 
mechanistic studies involving the transporter, and compared ethanol’s effect on 
DAT function and regulation. These data further our understanding of the 
molecular mechanism of intracellular ethanol action, and provides insight to 












Ethanol Action on Endosomal Recycling of Human Dopamine Transporters 
 
The following chapter has been submitted for publication, and is currently 
under review as: Riherd Methner, D.Nicole and R. Dayne Mayfield “Ethanol alters 
endosomal recycling of human dopamine transporters.” 2009. 
 
4.1 Introduction 
Dopamine (DA), a major central nervous system neurotransmitter, is 
involved in reward and reinforcing behaviors. DA signaling relies on a critical 
balance between release and removal of the neurotransmitter within synaptic 
clefts. Drugs of abuse, including psychostimulants and ethanol, cause 
maladaptive changes in DA signaling in mesolimbic areas of the brain, leading to 
addictive behaviors. Localized on pre-synaptic dopaminergic terminals, the 
dopamine transporter (DAT) is responsible for terminating DA signaling by rapidly 
removing the transmitter from the synaptic cleft region (Torres et al. 2003b). DAT 
and other monoamine transporters, including norepinephrine, γ-amino butyric 
acid, and serotonin (NET, GAT1, and SERT, respectively), clear extracellular 
transmitter via a reuptake mechanism (Nelson 1998).   
Regulation of DAT function is mediated by recycling of the transporters 
between intracellular compartments and the plasma membrane (Melikian and 
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Buckley 1999). This dynamic trafficking occurs in both a constitutive and 
regulated manner to increase or decrease the number of transporters on the cell 
surface that are available for transmitter reuptake. Trafficking modulators, such 
as activated protein kinase C (PKC), have been shown to alter basal transporter 
trafficking rates.  PKC-mediated regulation causes an intracellular accumulation 
of DAT by increasing internalization and decreasing insertion of the transporter 
on the cell surface (Loder and Melikian 2003).  In addition to intrinsic transporter 
modulators, various drugs of abuse are known to target monoamine transporters.  
DAT is the main site of action of several psychostimulants such as cocaine and 
amphetamines (Ritz et al. 1988, Sulzer et al. 1993, Jayanthi and Ramamoorthy 
2005).   Cocaine inhibited DAT and increased the number of transporters on the 
cell surface by altering DAT trafficking in rat striatum and heterologously 
expressing cells (Daws et al. 2002, Little et al. 2002, Chi and Reith 2003, Chen 
and Reith 2007).  Amphetamine produced an initial increase in cell surface 
populations of the transporter in rat striatal synaptosomes (Johnson et al. 2005), 
followed by internalization of cell surface transporters and DAT-mediated DA 
efflux (Saunders et al. 2000, Kahlig et al. 2006, Binda et al. 2008, Boudanova et 
al. 2008a).  Psychostimulant-induced modulation of transporter trafficking plays a 
critical role in mediating the mechanism of action of the drug.  
 Ethanol is also known to activate DA pathways in the reward and 
reinforcing areas of the brain. Many groups have shown that ethanol alters DA 
signaling by increasing release of the transmitter (Imperato and Di Chiara 1986, 
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Yoshimoto et al. 1992, Brodie and Appel 1998); however, recent in vitro studies 
from our lab suggest ethanol modulates DAT function as well.  Experiments in 
DAT-expresssing Xenopus laevis oocytes have shown ethanol potentiated 
[3H]DA uptake in a time- and concentration-dependent manner and enhanced 
transporter-mediated currents.  The ethanol-induced increase in DA uptake in the 
oocytes was accompanied by an increase in radioligand [3H]WIN 35,428 ([3H]2-β-
carbomethoxy-3β-(4-fluorophenyl)tropane) binding to DAT (Mayfield et al. 2001).  
Similar effects of ethanol on DAT function and surface localization were found 
when the transporter was expressed in neuroblastoma (SK-N-SH) or human 
embryonic kidney-293 cells (HEK-293) (Riherd et al. 2008).  Ethanol potentiation, 
however, is not observed among other monoamine transporters.  For example, 
ethanol inhibited uptake of the closely related NET (Lin et al. 1993, Maiya et al. 
2002).  The opposing effect of ethanol on DAT and NET led to identification of 
ethanol-sensitive sites in the first intracellular loop of DAT using chimeras 
between DAT and NET (Maiya et al. 2002).  Specifically, when glycine 130 
and/or isoleucine 137 were replaced with the corresponding NET residues, 
threonine and phenylalanine, respectively, the ethanol sensitivity of the 
transporter was abolished in oocytes (Maiya et al. 2002) and significantly 
reduced in SK-N-SH and HEK-293 cells (Riherd et al. 2008). The loss of ethanol 
sensitivity by these point mutations suggest ethanol alters DAT function or 
trafficking in a direct manner.   
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The ethanol-induced potentiation of DA uptake and increase in DAT cell 
surface expression suggest ethanol modulates transporter function by 
redistributing DAT to the cell surface. However, it is not known how or if ethanol 
directly regulates DAT trafficking.  In this study, we used [3H]DA uptake and 
biochemical methods to assess the pharmacological action of ethanol on DAT 
function and endosomal recycling.  Basal and ethanol-regulated rates of insertion 
and internalization of the transporter were measured in HEK-293 cells using 
modified biotinylation assays. We found ethanol modulates DAT function by 
increasing the rate of insertion while having no effect on DAT endocytosis, 
resulting in an accumulation of the transporter on the plasma membrane. These 
results suggest an additional mechanism by which ethanol can potentially affect 
synaptic dopamine dynamics in mammalian systems.  
 
4.2 Characterization of Ethanol Action on DAT and G130T DAT HEK Cells 
We first characterized ethanol action on DAT function in HEK-293 cells 
stably expressing DAT.  We also tested function of the ethanol-insensitive G130T 
DAT mutant.  DAT or G130T DAT was transfected into HEK-293 cells and 
selected for stable expression.  Stably expressing cells were incubated with 100 
nM [3H]DA for 3 min, and dopamine uptake was measured as the accumulation 
of [3H]DA into the cells. The G130T DAT mutation had no effect on basal [3H]DA 
uptake (Figure 4.1.A).  Cells were pretreated with ethanol (10, 50, 100 mM) for 5, 
30 or 60 min.  Ethanol potentiated [3H]DA uptake in DAT HEK cells in a 
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concentration-, but not time-dependent manner (Figure 4.1.B, upper panel).  
Compared to untreated DAT HEK cells, 100 mM ethanol produced a 66-77% 
increase in uptake at all time points. Ethanol had no significant effect on G130T 
DAT HEK mediated [3H]DA uptake compared to untreated G130T DAT HEK cells 



















Figure 4.1: Functional characterization of ethanol action on DAT and 
G130T DAT HEK cells.  Uptake of [3H]DA was measured in stably 
expressing DAT or G130T DAT HEK cell cultures. A. Basal  [3H]DA uptake 
was unchanged (n.s.: not significant) by the G130T mutation.  (unpaired t 
test; n=7 experiments with triplicate samples) B. Stably expressing DAT or 
G130T DAT HEK cells were exposed to ethanol (10, 50 or 100 mM) for 0, 5, 
30 and 60 min at 25°C.  Upper panel, Ethanol potentiated DAT-mediated 
[3H]DA uptake in a concentration-dependent manner compared to controls 
(*p < 0.05 or **p < 0.01, one-way ANOVA with post-hoc analysis for linear 
trend; n=5 experiments per time point with triplicate samples). Bottom panel, 
The G130T DAT mutation abolished ethanol sensitivity of the transporter.  
(unpaired t test for individual ethanol concentration comparisons to controls; 
n=5 experiments per time point with triplicate samples. Values represent 
mean ± S.E.M. 
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4.2.1 Comparison of DAT and G130T DAT HEK surface localization after 
ethanol exposure 
We have recently demonstrated that ethanol increases cell surface 
populations of DAT in HEK-293 cells (Riherd et al. 2008).  However, the 
mechanisms underlying these changes were unknown.  We first verified ethanol-
induced changes on DAT surface populations by comparing its effect on DAT 
and G130T DAT surface localization.  We used biotinylation assays to assess 
cell surface transporter levels in DAT HEK cells after 1 hr incubation with 100 
mM ethanol at 37°C (see representative immunoblot, Figure 4.2.B).  eGFP 
conjugated DAT or G130T DAT is ~70-120 kDa, depending on glycosylation 
state. Under control conditions, 30.4% ± 3.6 of the total DAT population was 
expressed on the cell surface, while ethanol-exposed cells were found to have 
50.6% ± 4.4 of the total DAT population on the surface (Figure 4.2.B).  In 
agreement with our previous study (Riherd et al. 2008), ethanol significantly 
increased DAT surface expression ~40-45% while having no effect on the total 
cellular population of the transporter (data not shown). To determine if ethanol 
has a global, non-specific effect on cellular trafficking, blots were re-probed for 
TfR, an endogenous protein that also undergoes endosomal recycling (Figure 
4.2.A).  Basal cell surface levels of TfR in DAT HEK cells were not significantly 
changed by ethanol (11.4% ± 1.5 compared to 11.6% ± 1.7 of total TfR for 
control and 100 mM ethanol-exposed cells, respectively) (Figure 4.2.B).  We 
repeated the cell surface biotinylation experiments with G130T DAT HEK cells, 
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which were functionally insensitive to ethanol (see representative immunoblot, 
Figure 4.2.C).  Ethanol had no significant effect on the number of mutant 
transporters on the cell surface (33.7% ± 1.9 compared to 29.5% ± 0.7 of total 
G130T DAT for control and 100 mM ethanol-exposed cells, respectively) or the 
number of TfR (13.3% ± 1.3 compared to 12.5% ± 2.3 of total TfR for control and 
100 mM ethanol exposed cells, respectively) (Figure 4.2.D).  DAT and G130T 
DAT immunoblots were re-probed with an antibody against the intracellular 
marker, CAL (Figure 4.2.A and C).  The integrity of the plasma membrane was 
maintained throughout the course of the biotinylation assay (<2% of total calnexin 














Figure 4.2: Ethanol promotes DAT surface localization.  DAT and G130T 
DAT HEK cells were incubated for 60 min at 37°C ± 100 mM ethanol.  Cell 
surface levels of the transporter were determined using surface biotinylation 
assays.  (A and C) Representative immunoblots of total (Total) and biotinylated 
(Surface) populations of transporter, TfR and calnexin (CAL) in (A) DAT HEK 
cells or (C) G130T DAT HEK cells in the absence (-) or presence (+) of 100 mM 
ethanol. Total populations of transporter, TfR and calnexin were unchanged by 
ethanol in DAT and G130T DAT HEK cells. (B and D) Densitometric analysis of 
surface transporter and TfR immunoblots (surface levels were calculated as 
percent of total cellular DAT or TfR) expressed in (B) DAT HEK or (D) G130T 
DAT HEK cells (control, open bars; 100 mM ethanol, closed bars).  Ethanol 
significantly increased surface expression of DAT by ~40% (*p < 0.05, unpaired 
t test; n=3) but had no significant effect on surface levels of G130T DAT (n=3).  
Ethanol had no effect on TfR levels in DAT or G130T DAT HEK cells.  Values 
represent mean ± S.E.M.  
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4.3 Ethanol Action on DAT Endosomal Recycling Pool Size 
To elucidate how ethanol modulates the cell surface DAT population, we 
first determined if ethanol increases DAT on the surface by altering the overall 
size of the endosomal recycling pool.  For these experiments, we used a 
modified biotinylation assay described previously (Wang and Quick 2005).  Biotin 
was applied to the cells in trafficking permissive temperatures (37°C).  Cell 
surface proteins and proteins inserted in the plasma membrane were labeled by 
biotin during the course of the assay (see representative immunoblot, Figure 
4.3.A).  The biotinylated DAT fraction was compared to total cellular DAT to 
estimate the overall recycling pool size.  Under basal conditions, 70-80% of the 
total DAT population was biotinylated after 30 min of trafficking and remained 
unchanged up to 90 min (data not shown).  The size the DAT recycling pool was 
not significantly altered by 100 mM ethanol over the course of 60 min (70.2% ± 
4.9 compared to 71.9% ± 9.2 of total DAT for vehicle and 100 mM ethanol 











4.4 Effects of Ethanol on DAT Cell Membrane Insertion Rate 
DAT expression in the plasma membrane is regulated by a dynamic  
balance of transporter insertion in the cell membrane and endocytic 
internalization.  We next asked if the ethanol-induced upregulation of cell surface 
DAT was due to changes in either one of these trafficking mechanisms. First, we 
determined if ethanol altered the rate of transporter insertion into the plasma 
membrane.  For these experiments, we used modified biotinylation assays to 
measure DAT delivery to the cell surface over time.  Assays were performed at 
25°C to slow trafficking in order to accurately monitor ethanol action on 
transporter recycling.  DAT HEK cells were first biotinylated under trafficking-
Figure 4.3: DAT recycling pool size is unchanged by ethanol.  DAT 
HEK cells were exposed to 1 mg/ml biotin in the absence (-) or presence 
(+) of 100 mM ethanol for 60 min at 37°C (trafficking permissive).  A. 
Representative immunoblot of total (Total) and recycling pool populations 
(Biotinylated) of DAT ± 100 mM ethanol.  B. Densitometric analysis of DAT 
recycling pool immunoblots.  Biotinylated transporter represents DAT 
within endosomal recycling pools (recycling pool size was calculated as 
biotinylated protein / total cellular DAT after 30,60, and 90 min of 
trafficking.  Ethanol had no significant effect on DAT recycling pool size 
(unpaired t test, n=3).  Values represent mean ± S.E.M.  
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restrictive conditions (4°C) to label all surface transporters at 0 min (t =0).  Cells 
were then incubated with biotin in trafficking permissive temperatures (25°C) for 
0, 2, 5, 15 or 30 min (t) in the absence or presence of 100 mM ethanol.  
Biotinylated DAT was calibrated to the respective total cellular DAT for each time 
point.  Newly inserted transporter levels were determined by comparing the 
percent increase in biotinylated DAT fractions at t = 2, 5, 15 or 30 min over DAT 
surface levels at t = 0 (see representative immunoblot, Figure 4.4.A).  Data were 
fit to a single exponential function as described in Experimental Procedures 
(Figure 4.4.B), and estimations of basal and ethanol-modulated insertion rates 
were calculated (0.06 min-1 ± 0.01 and 0.24 min-1 ± 0.04 for control and 100 mM 
ethanol exposed cells, respectively).  Both vehicle (control) and ethanol-exposed 
DAT HEK cells reached a plateau after 30 min where ~75% of total DAT was 
biotinylated. Ethanol significantly increased DAT insertion rate by ~4-fold.  
Immunoblots were re-probed for TfR (see representative immunoblot, Figure 
4.4.C). Ethanol had no significant effect on TfR insertion rates in DAT HEK cells 
(0.22 min-1 ± 0.09 and 0.26 min-1 ± 0.12 for vehicle and 100 mM ethanol exposed 
















Figure 4.4:  Ethanol increases DAT insertion rates.  Transporter insertion 
into the membrane was observed using a modified biotinylation assay.  (A and 
C) Representative immunoblots of total lysate (T) and biotinylated (B) 
populations of (A) DAT and (C) TfR in DAT HEK cells. Biotinylated samples 
represent newly inserted proteins into the cell surface at 25°C at 0, 2, 5, 15 and 
30 min ± 100 mM ethanol.  (B and D) Densitometric analysis of immunoblots 
plotted as a time course of (B) DAT and (D) TfR insertion into the cell surface of 
DAT HEK cells (control (); 100 mM ethanol ()).  Biotinylated proteins were 
calibrated to their respective total populations, and insertion was determined as 
the percent increase of biotinylated protein compared to basal surface levels at t 
= 0 min. Data were fit to a first order exponential equation as described in 
Experimental Procedures to calculate insertion rate.  (B) Ethanol significantly 
increased DAT insertion rate compared to controls by ~ 4-fold (p < 0.01, F test). 
(D) Ethanol had no effect on TfR insertion into the surface of DAT HEK cells.  




4.5  Effects of Ethanol on DAT Internalization Rate 
We next determined if ethanol altered endocytic internalization using 
reverse biotinylation assays.  Transporters were labeled with biotin at trafficking-
restrictive temperatures (4°C).  Unbound biotin was removed, and cells were 
warmed to 25°C for 0, 2, 5, 15 or 30 min in the absence or presence of 100 mM 
ethanol. Cell surface-bound biotin was removed by an extracellular reducing 
agent.  The remaining biotinylated DAT fraction represents internalized 
transporter.  Internalized transporter was compared to the total surface (T.S.) 
DAT at t=0 (see representative immunoblot, Figure 4.5.A).  Strip control samples 
indicate that 90-95% of biotin was removed during TCEP stripping washes (data 
not shown). Data was fit to a single exponential function as described in 
Experimental Procedures (Figure 4.5.B), and relative internalization rates were 
calculated (0.54 min-1 ± 0.09 and 0.6 min-1 ± 0.18 for control and 100 mM ethanol 
exposed cells, respectively). After 15 min, intracellular accumulation of 
transporter reached a plateau where 66.9% ± 2.6 or 38.13% ± 2.4 of total DAT 
was internalized in vehicle or ethanol-exposed cells, respectively.  Ethanol had 
no significant effect on the rate of internalization.  For TfR in DAT HEK cells (see 
representative immunoblot, Figure 4.5.C), ethanol had no significant effect on the 
total number of internalized receptors  (38.2% ± 2.7 and 37.0% ± 2.8 of total TfR 
for vehicle and 100 mM ethanol-exposed cells, respectively) (Figure 4.5.D) or the 
internalization rate (0.18 min-1 ± 0.05 and 0.20 min-1 ± 0.08 for vehicle and 100 













Figure 4.5: Ethanol has no effect on WT DAT internalization rates.  
Internalization of transporter was determined using reverse biotinylation assays. 
Intracellular accumulation of DAT and TfR in DAT HEK cells was measured at 
2, 5, 15 and 30 min at 25°C ± 100 mM ethanol. (A and C) Representative 
immunoblots of basal total surface (T.S.) and internalized proteins in (A) DAT 
and (C) TfR in DAT HEK cells ± 100 mM ethanol. (B and D) Densitometric 
analysis of immunoblots plotted as a time course of (B) DAT and (D) TfR 
internalization from the cell surface of DAT HEK cells (control (); 100 mM 
ethanol ()). Total number of internalized proteins was calculated as the 
percent of biotinylated protein at each time point compared to basal total 
surface levels (T.S.; t = 0). Data were fit to a first order exponential equation as 
described in Experimental Procedures to calculate internalization rate. (B) The 
total number of internalized DAT significantly decreased by ~50% after ethanol 
treatement (p < 0.01, F test comparison of time course maximums between 
control and ethanol treated cells) but produced no significant effect on 
internalization rate of the transporter.  (D) Ethanol had no effect on the total 
number of internalized TfR or internalization rate. Graphs represent the average 





4.6  Discussion 
Previous in vitro studies in DAT-expressing Xenopus oocytes and 
heterologous cell expression systems have shown ethanol potentiates [3H]DA 
uptake (Mayfield et al. 2001, Riherd et al. 2008).  Kinetic analysis of [3H]DA 
uptake revealed these changes were not due to alterations in the binding affinity 
of the transporter for dopamine (Riherd et al. 2008).  Ethanol-induced increases 
in transporter function were associated with an increase in [3H]WIN 35,428 DAT 
binding and expression on the cell surface, suggesting ethanol may alter 
transporter trafficking (Mayfield et al. 2001, Riherd et al. 2008).  However, the 
subcellular mechanisms underlying ethanol-mediated regulation of DAT surface 
expression are unknown.  In this study, we found ethanol increases DAT-
mediated [3H]DA uptake by altering endosomal recycling of the transporter.  Our 
data suggest ethanol increases the rate of insertion of DAT into the cell 
membrane, while having no effect on the rate internalization.  These ethanol-
induced modulations of the DAT endosomal trafficking pathway result in a net 
increase of functional transporters on the cell surface.  
For these experiments, we used HEK-293 cells stably expressing DAT 
which were developed in a previous study (Riherd et al. 2008).  The DAT HEK 
cells were utilized to directly examine the pharmacological action of ethanol on 
transporter function and trafficking. For comparison of function and surface 
localization, we developed another stable line of HEK-293 cells expressing an 
ethanol-insensitive mutant, G130T DAT.  The G130T mutation was developed 
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from chimeric studies between DAT and NET (Maiya et al. 2002).  Although 
closely related in structure and function, previous studies showed ethanol has 
opposing effects on DAT and NET (Lin et al. 1993, Lin et al. 1997, Maiya et al. 
2002).  G130T DAT HEK cells were used in this study as a tool to determine if 
DAT sensitivity to ethanol was mediated by specific alterations in surface 
expression of the transporter.   Finally, we used a biochemical approach to 
investigate ethanol-induced changes on endosomal recycling of DAT.  Examining 
ethanol modulation of trafficking in vitro allows us to determine the direct 
pharmacological actions of ethanol on intracellular trafficking of the transporter.  
A caveat to this approach is that we can only determine the relative rates and 
changes in intracellular trafficking. The use of cell lines, which over express the 
transporter, does not allow for an accurate measurement of recycling rates found 
in intact neurons.  However, this experimental approach allowed us to determine 
ethanol-induced changes on the distinct steps involved in endosomal recycling 
and yielded novel insights into the mechanisms of ethanol action on subcellular 
trafficking of the transporter. 
Characterization of DAT and G130T DAT function revealed the G130T 
mutation had no effect on basal [3H]DA uptake; however, the point mutation 
abolished the ethanol sensitivity of transporter function. In contrast, previous 
observations with HEK-293 and neuronal SK-N-SH cell lines transiently 
expressing transporters showed that G130T reduced, but did not eliminate, 
ethanol sensitivity in these mammalian cell expression systems (Riherd et al. 
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2008).  In these studies, stable expression of the transporters reduced variability 
in [3H]DA uptake assays compared to cells used in our previous study, which 
transiently expressed the transporters.  This reduction of variability between 
assays in the current study likely contribute to these differences in [3H]DA 
uptake.  
Analysis of ethanol-induced changes in DAT and G130T DAT surface 
expression indicated ethanol sensitivity of DAT was mediated by changes in 
surface expression and was specific for DAT.  Ethanol induced a significant 
increase in cell surface DAT but had no effect on expression of G130T DAT in 
the membrane.  Immunoblots revealed a population of the mutant transporter at 
~65-70 kDa.  This population likely contains immature transporter retained in the 
endoplasmic reticulum (ER).  While the mutation does not interfere with known 
export, oligmerization or ER-retention motifs (Miranda et al. 2004), mutation of 
glycine 130 may alter folding of a portion of the transporter population, thus 
preventing export from the ER.  However, a large portion of functional G130T 
transporter population is trafficked out of the ER.  Ethanol had no effect on the 
surface populations of mutant transporter, and misfolding does not likely 
contribute to the lack of an ethanol effect on G130T DAT surface expression. The 
mutation also does not interfere with known residues critical in DAT surface 
retention (Sorkina et al. 2009).  Therefore, ethanol-induced alteration of DAT 
surface expression does not appear to involve known signaling sequences 
required for constitutive trafficking of the transporter (Holton et al. 2005).  Ethanol 
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also does not affect total cellular transporter levels or the size of DAT endosomal 
recycling pools.  While not tested directly, these data suggest ethanol does not 
alter synthesis, secretion or lysosomal degradation of transporter. Endogenous 
TfR surface expression was also not altered by ethanol, confirming ethanol does 
not have a non-specific effect on endosomal trafficking.  These results indicate 
the following: (i) ethanol-induced potentiation of DAT function is mediated by 
changes in surface expression of the transporter, (ii) this sensitivity is specific to 
DAT and (iii) ethanol-induced increase in surface expression is likely due to 
alterations in the endosomal recycling pathway and not overall expression 
changes.  
Dynamic membrane trafficking of neurotransmitter transporters is 
essential for efficient regulation of the duration and strength of synaptic 
neurotransmission (Jayanthi and Ramamoorthy 2005).  The balance between 
insertion and endocytic internalization of transporters within the recycling 
pathway maintains homeostatic transmitter levels.  DAT and other 
neurotransmitter transporters recycle in a constitutive manner. However, intrinsic 
and pharmacological modulators can also regulate endosomal recycling, 
mediating changes in neurotransmission (Yu et al. 2000, Whitworth and Quick 
2001b, Whitworth and Quick 2001a, Whitworth et al. 2002, Granas et al. 2003, 
Holton et al. 2005, Jayanthi and Ramamoorthy 2005, Maiya et al. 2006). 
Alterations in cell surface transporter expression arise from modulation of 
transporter insertion, internalization or both steps of the recycling pathway. For 
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example, amphetamine-regulated DAT trafficking results in a suppression of 
transporter insertion and stimulation of endocytic rates, causing an overall 
decrease in surface levels of the transporter (Boudanova et al. 2008a).  Here we 
show that ethanol modulates distinct steps in the endosomal recycling of DAT.  
These novel findings suggest ethanol elevates surface expression of the 
transporter by increasing the rate of DAT insertion and without affecting the rate 
of internalization. The reduction of the overall number of transporters internalized 
by ethanol was likely a refection of depleted internal endosomal pools caused by 
the significant increase in insertion rate.  Ethanol had no effect on TfR 
endosomal recycling, suggesting that TfR and DAT recycle in separate 
endosomal pools, and ethanol does not induce a generalized effect on trafficking 
of endosomes.    
The molecular components involved in ethanol-induced regulation of DAT 
recycling are unknown.  DAT does not contain classical trafficking signal 
sequence sites such as tyrosine- or dileucine-based motifs (Holton et al. 2005).  
Monoamine transporters are subject to regulation by PKC-dependent 
mechanisms; however, kinase-mediated phosphorylation is not required in 
regulated or constitutive trafficking of DAT (Chang et al. 2001). Furthermore, 
ethanol-sensitive areas of the transporter do not contain phosphorylation sites, 
suggesting ethanol-induced modulation of trafficking is not mediated through 
changes in the phosphorylation state of DAT.  Accessory proteins are likely 
involved in ethanol modulation of exocytic insertion.  Emerging evidence 
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suggests rapid regulation and clustering of other neurotransmitter transporters is 
dependent on interaction with microfilament proteins (Duan et al. 1999, Zhou and 
Sutherland 2004, Mochizuki et al. 2005, Imoukhuede et al. 2009).  Ethanol has 
been found to reorganize the actin and microtubulin cytoskeleton involved in the 
glucose transporter trafficking, altering glucose uptake (Tomas et al. 2003). 
Further investigation is needed to define the trafficking proteome, and ethanol 
action on those protein-protein interactions (Torres 2006).  In summary, the 
present study has revealed that ethanol modulates the DAT endosomal recycling 
pathway, thus directly altering transporter function.  These novel findings are the 
first to describe ethanol effects on specific steps of the transporter trafficking 
pathway, and provide a framework to further understand the action of ethanol on 









The dynamic trafficking of DAT is critical in regulation of the transporter, and 
dopaminergic signaling.  As outlined in chapter one, DAT trafficking occurs in a 
constitutive and regulated manner.  The transporter recycles to the cell surface 
from intracellular endosomal pools to regulate DA levels in rapid and efficient 
manner.  Multiple second messenger systems and various drugs of abuse can 
regulate transporter function by altering the cell surface distribution of the 
transporter. For example PKC activation and amphetamine cause an 
internalization of DAT in a clathrin- and dynamin-dependent manner (Zhang et al. 
1997, Daniels and Amara 1999, Melikian and Buckley 1999, Saunders et al. 
2000).  Acute exposure of cocaine enhances DAT activity by altering intracellular 
trafficking of the transporter, increasing DAT cell surface expression (Daws et al. 
2002, Little et al. 2002).  Evidence presented in chapters three and four suggest 
ethanol also regulates DAT function by altering endosomal recycling of the 
transporter.   
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The molecular components and trafficking proteome involved in DAT 
trafficking remain unclear.  The transporter does not contain classical trafficking 
signaling consensus sites (Holton et al. 2005), and phosphorylation of the 
transporter is not required for constitutive or regulated trafficking (Chang et al. 
2001).  Trafficking of DAT could be modulated by changes in protein-protein 
interactions.  Intracellular loops are accessible to interaction with accessory 
proteins, and modifying enzymes (Quick et al. 1997).  Ethanol-induced regulation 
of the transporter is mediated by critical amino acids in the first intracellular loop, 
none of which are contained in phosphorylation consensus sites (Maiya et al. 
2002, Riherd et al. 2008). Studies in chapter four suggest mutation of G130 in 
IL1 alters DAT sensitivity to ethanol by inhibiting the trafficking-dependent 
upregulation of DAT surface localization.  Chimera studies between DAT and 
NET, which is inhibited by ethanol, in Xenopus oocytes suggest this loop is 
critical in DAT trafficking and ethanol-mediated regulation of transporter 
trafficking.   
NET and DAT share a high degree of homology in amino acid sequence and 
function.  The two transporters differ by four amino acids in IL1, DAT residues 
F123, G130, I137, and L138.  In Xenopus oocytes, individual point mutations of 
G130 and I137 reduced ethanol sensitivity of the transporter, while F123 and 
L138, demonstrated no significant ethanol-induced changes (Maiya et al. 2002).  
Mutation of all four sites to the homologous NET residues resulted in a complete 
abolishment of [3H]DA uptake and [3H]WIN 35,428 surface binding of DAT in 
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oocytes.  These results suggest IL1 is important in constitutive and ethanol-
regulated trafficking of the transporter to the cell surface. 
The objective of aim three is to characterize the function and cellular 
localization of the IGLF DAT in mammalian cells.  The generation and 
characterization of the IGLF mutant may be important in future studies identifying 
protein interactions critical in DAT trafficking.  We hypothesize IGLF DAT uptake 
function will be abolished as a result of deficiencies in cell membrane trafficking.   
  
5.2 Functional Characterization of IGLF DAT HEK 
Stably expressing IGLF DAT HEK cells containing an eGFP tag were 
generated, as described in chapter two.  Clonal colonies were selected, and 
expanded based on IGLF DAT expression monitored by fluorescence 
microscopy.  Colonies with 90-100% of the cells expressing the mutant were 
selected for expansion, and expression was verified with immunoblotting (Figure 
5.1.A).  The function of IGLF DAT was examined using [3H]DA uptake assays. 
Stably expressing DAT or IGLF DAT cells were incubated with 20 nM [3H]DA for 
3 min, and dopamine uptake was measured as the accumulation of [3H]DA into 
the cells.  Compared to DAT HEK cells (0.15 ± 0.02 pM/min/ 0.05x105 cells) the 
IGLF DAT cells exhibited a complete abolishment of  [3H]DA uptake function (-
0.0003 ± 0.0002 pM/min/ 0.05x105 cells) (Figure 5.1.B). 
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5.3 Cell Surface Expression Analysis of IGLF DAT 
Cell surface expression of IGLF DAT was measured to determine if the inhibition 
of [3H]DA DAT-mediated  uptake was due to a lack of transporters on the cell 
surface.  Biotinylation assays, a direct measure of cell surface protein 
expression, were used to compare surface localization of DAT and IGLF DAT.  
The cell surface population of proteins was measured as a percentage of the 
total amount of the respective cellular populations (Figure 5.2).  Surface DAT 
levels (36.6% ± 8.5 of total DAT population) were not significantly different from 
surface IGLF DAT levels (24.4% ± 4.2 of total IGLF DAT populations).  Blots 
Figure 5.1:  IGLF mutation of 
DAT abolishes transporter 
function. A. DAT or IGLF DAT 
was stably expressed in HEK-293 
cells.  Expression was verified by 
immunoblotting with DAT antibody 
(MAB 369). Representative 
immunoblot of ~80µg total lysate.  
B. Basal transporter-mediated 
[3H]DA uptake.  The IGLF 
mutation abolished transporter 
function (*p < 0.01 compared to 
DAT HEK; unpaired t test; n= 7 




were stripped and reprobed with a TfR antibody, an endogenous protein which 
undergoes endosomal recycling.  Cells stably expressing the IGLF mutant also 
had no significant difference in TfR levels compared DAT HEK cells (8.6% ± 0.4 









The objective of aim three was to characterize IGLF DAT function and 
surface localization in mammalian cell systems in order to potentially use the 
mutant as a tool in delineating the molecular mechanisms of transporter 
trafficking.  IGLF DAT function was completely abolished, however surface levels 
of the mutant were not significantly different from cells expressing wild-type 
Figure 5.2:  The IGLF DAT mutation has no effect on surface localization.  
A. Representative immunoblot of total (Total) and biotinylated (Surface) 
populations of transporter and TfR in DAT HEK cells (DAT) or IGLF DAT HEK 
cells (IGLF). B.  Desitometric analysis of surface transporter and TfR 
immunoblots.  Surface expression was calculated as perecent of total cellular 
DAT or TfR expressed in DAT HEK or IGLF DAT HEK cells. Total and surface 
populations of transporter (DAT and IGLF) and TfR were unaffected by the 
IGLF mutation (unpaired t test; n=3). Values represent mean ± S.E.M. 
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transporter (DAT HEK).  These results were unexpected, and differ from the 
findings from Xenopus oocytes (Maiya et al. 2002), which suggested the 
inhibition of the mutant transporter function was due to an impairment of 
trafficking to the cell surface.     
Discrepancies between the transporter cell surface localization results from 
this study and those found using the Xenopus expression system are likely due 
to differences in the methods used to measure surface expression.  In the 
Xenopus oocyte expression system, surface localization of DAT was measured 
using [3H]WIN 35,428 binding. [3H]WIN 35,428 is a potent cocaine analog, and 
binds to the cocaine-binding site of the transporter, which overlaps the DA 
binding site.  In this study, surface expression was measured directly using a 
biochemical labeling method, biotinylation.  Both the mammalian cell and 
Xenopus expression systems expressing IGLF DAT demonstrated a lack of 
function. These results suggest IGLF mutant DAT cannot bind or translocate DA, 
which is likely the reason [3H]WIN 35,428 binding could not detect transporter on 
the cell surface.    
The IL1 of DAT is not required for constitutive trafficking of the transporter to 
the cell surface as previously speculated (Maiya et al. 2002), but may play a role 
in the conformational requirements of DAT for DA binding.  This hypothesis is 
supported by analysis of the LeuTAa crystal structure, which suggests TM3 and 
TM8 shift during DA binding and translocation into an inward-facing position, 
expanding IL1 and allowing DA permeation (Yamashita et al. 2005).  A crystal 
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structure depicting an unbound transporter is not available, but the analysis of 
the role of IL1 in the translocation of substrate in LeuTAa structure suggests the 
mutations of IGLF DAT may cause DAT to be maintained in the inward-facing 
position, not allowing for DA binding. Interestingly, a study examining the role of 
DAT TM2 in cocaine binding found mutation of Q122, the residue immediately 
adjacent to F123 mutated in IGLF DAT, also resulted in a transporter which 
lacked function which was expressed on the cell surface (Sen et al. 2005).  The 
researchers suggested the cytoplasmic face of TM2/IL1 (location of Q122 and 
F123) region interacts with TM6, one of the regions directly involved in substrate 
binding.  The mutations likely perturb the interaction of TM2-TM6, causing the 
transporter to be maintained in the inward-facing position, and indirectly inhibiting 
ligand binding.  Further investigation of the IGLF DAT-induced conformational 
changes, and its role in DA binding is needed to confirm this hypothesis.  
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Chapter Six: Discussion 
 
The midbrain dopaminergic system, which includes DA neurons projecting to 
the striatum, NAc, and the PFC from the SN and VTA,  plays a central role in 
mediating the reward and reinforcing effects of drugs of abuse (Hyman et al. 
2006). These drugs, including psychostimulants and ethanol, elevate synaptic 
DA levels, mediating reinforcement.  Proper regulation of DA neurotransmission 
maintains homeostatic levels of the transmitter in active synaptic zones, and is 
mediated by a reuptake mechanism by the monoamine transporter, DAT.  
Localized on the peri-synaptic areas of pre-synaptic DA terminals, DAT is the 
primary site of action of several psychostimulants, including cocaine and 
amphetamine.  Psychostimulants elevate DA levels by blocking DAT-mediated 
DA reuptake, and ethanol increases the transmitter level by enhancing DA 
release (Gainetdinov and Caron 2003, Gonzales et al. 2004).  Unlike other drugs 
of abuse, ethanol is known to alter the function of multiple neurotransmitter 
systems and proteins in many brain regions.  The findings presented from the 
present studies outline the potential role of ethanol in altering the function and 
regulation of DAT. 
 
6.1 Ethanol Action on DAT Function in Mammalian Systems 
  Ethanol alters various properties of the dopaminergic system, including 
enhancing synaptic DA concentrations by increasing release of the transmitter 
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(Imperato and Di Chiara 1986, Di Chiara and Imperato 1988, Weiss et al. 1993, 
Yim and Gonzales 2000).  Few studies have investigated the role of transporters 
on ethanol-induced changes in synaptic transmission. The effects of ethanol on 
DAT-mediated DA regulation are controversial.  Our studies suggest that short-
term ethanol exposure potentiates DAT function in a concentration-dependent 
manner when expressed in mammalian cells.  These results are in agreement 
with previous findings in Xenopus oocytes expressing the transporter. However, 
in vivo and ex vivo electrochemical studies, including results from microdialysis, 
voltametry, and chronoamperometry, suggest ethanol may increase, decrease or 
have no effect on DA clearance (Wang et al. 1997, Budygin et al. 2001, Sabeti et 
al. 2003, Robinson et al. 2005, Mathews et al. 2006).   
The varied findings from electrochemical experiments are likely a 
reflection of the differences in experimental methods, electrical stimulation, 
mechanisms of ethanol administration, and ethanol concentration.   For example, 
researchers using the quantitative no-net-flux microdialysis technique have 
suggested ethanol-induced DA increases in rat NAc are not due to an inhibition 
of DAT activity (Yim and Gonzales 2000).  The investigators also found dialysate 
DA levels return to baseline while extracellular ethanol concentrations remain 
high.  The temporal difference in dialysate DA and ethanol levels could result 
from increased transporter function (Mayfield et al. 2001), however, this 
technique provides only an indirect measurement of transporter activity, and 
cannot measure potential increases in uptake (Yim and Gonzales 2000, Tang et 
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al. 2003a).  The microdialysis technique also has a low temporal resolution with 
dialysate sampling taking 5 to 20 min per a sample, potentially missing transient 
drug-induced changes in DA clearance.    
Voltammetry allows for a better temporal resolution, however the in vivo 
prep requires animals to be anesthetized during the experiment.   There are 
relatively few studies investigating the effects of anesthesia on DAT.  However, it 
has been reported that chloral hydrate, propofol, ketamine, halothane and 
isoflurane alter DAT uptake kinetics and/or cell surface expression (Shahani et 
al. 2002, Sabeti et al. 2003, Byas-Smith et al. 2004), suggesting anesthesia may 
alter results from voltammetry studies of DAT-mediated DA uptake.  
Measurements of DAT activity in mammalian cell expression systems 
allow for a direct assessment of transporter activity and potential correlation with 
changes in DAT regulation.  However, this in vitro approach may lack potentially 
vital cellular connections and cell- tissue-specific signaling needed for a gross 
assessment of the drug on an organism level. The in vitro model is beneficial in 
analyzing the pharmacological drug action on specific proteins.  In vitro 
investigations of ethanol action on DAT expressed in neuronal and non-neuronal 
mammalian expression systems, have suggested ethanol enhances transporter 
function only in neurons (Ho and Segre 2001).  However, we found ethanol 
potentiates DAT when expressed in neuronal or non-neronal cell lines, 
suggesting ethanol does not require a neuronal cell-specific pathway. Differences 
between these studies could be attributed to cell type and/or transfection 
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efficiencies.   The study conducted by Ho and Segre (2001) compared CHO cells 
to Neuro2A neuroblastoma cells to examine neuronal cell-specific effects of the 
transporters.  Others have found this cell line is particularly sensitive to passage 
number when transiently expressing protein, including DAT, resulting in changes 
of basal DA uptake kinetics, and possible discrepancies in drug-induced changes 
of function (Ukairo et al. 2007).   
When we transiently expressed DAT into SK-N-SH or HEK-293 cells, 
ethanol-induced potentiation of function was variable and lacked an overall 
concentration-dependent pattern of uptake.  The G130T DAT transient 
expression resulted in a significant, but lower, potentiation of uptake.  These 
differences could be attributed to 1) variability of transient transfection 
expression, 2) low level of endogenous DAT in SK-N-SH cells, 3) leaky 
membranes from transfection methods, or 4) lack of an ethanol effect in 
mammalian systems.  In contrast, stable expression of the transporter revealed a 
concentration-dependent effect of ethanol (chapter four), suggesting the 
variability of uptake between assays in the earlier study (chapter three) was a 
result of variability of transient expression. Furthermore, a point mutation of one 
amino acid in IL1 of DAT (G130), alters this sensitivity, also suggesting ethanol 
modulates DAT in a direct manner.  Overall, our findings in mammalian cells are 
consistent with previous studies in a Xenopus expression system system 




6.2 Ethanol-Mediated Alterations of DAT Regulation 
Ethanol-induced enhancement of DAT-mediated uptake correlated with an 
increase in cell surface expression of the transporter.  The G130T DAT mutant 
was insensitive to ethanol, and surface expression of the mutant did not change 
after ethanol exposure.  These findings further suggest ethanol-induced changes 
of transporter function are trafficking mediated.  The focus of the second aim was 
to determine the mechanism involved in mediating redistribution of DAT to the 
cell surface.  Short-term ethanol exposure could enhance cell surface expression 
of the transporter by several mechanisms 1) increasing the number of DAT in the 
endosomal recycling pool 2) increasing the rate of insertion 3) decreasing the 
rate of internalization or 4) a combined effect of increasing insertion and 
decreasing internalization.   
For these studies we assessed cell surface trafficking rates of the 
transporter using modified and reverse biotinylation assays. The advantage to 
the biotinylation method is that it allows us to directly assess recycling of 
transporters over time, and monitor insertion and internalization separately. The 
use of these assays in measuring transporter trafficking is relatively new (Wang 
and Quick 2005) and has never been used to detect drug-induced action on 
multiple steps of the DAT trafficking pathway.  Caveats to this approach are that 
we cannot directly compare rates of insertion to rates of internalization due to 
differences in the experimental methods, and the use of cell lines, which over 
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express the transporter, does not allow for an accurate measurement of recycling 
rates as found in intact neurons.  However, this experimental approach allowed 
us to pinpoint ethanol-induced changes on the distinct steps involved in 
endosomal recycling and yielded novel insights into the mechanisms of ethanol 
action on subcellular trafficking of the transporter. 
Due to the ubiquitous effects of ethanol, we considered that ethanol  might 
affect multiple steps of the endosomal recycling pathway.  However, we found 
ethanol only modulated insertion of the transporter (Figure 6.1).  Furthermore, 
ethanol had no effect on endogenous proteins that undergo similar endosomal 
recycling or the size of the DAT endosomal recycling pool.  These results 
suggest ethanol effects were specific to the transporter, and did not alter the 




Figure 6.1:  Ethanol action on DAT endosomal recycling.  Ethanol potentiates DAT 
function by increasing the rate of insertion, causing an enhancement of cell surface 
localization of DAT.  Internalization and DAT recycling pool size are not altered by ethanol.  
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The mechanism of ethanol-induced changes on the exocytic insertion of DAT 
remains unclear and could involve several molecular components the DAT 
trafficking proteome. Future analysis of DAT, compared to the ethanol-insensitive 
G130T DAT, could yield insight into potential protein interactions disrupted by 
ethanol.  DAT does not contain classical trafficking signal motifs, and its non-
classical signal motif, which is conserved among all monoamine transporters, 
was identified in the C-terminal region of the transporter.  We found the IL1 was 
important in mediating ethanol sensitivity; therefore, ethanol does not appear to 
interfere with interactions with this motif.   
The G130T mutation does not interfere with known phosphorylation sites.  
However, potential ethanol-mediated changes in kinase activity could alter 
transporter trafficking indirectly via other kinase-stimulated protein interactions.  
Interestingly, one difference between NET and DAT is the effect of PKA pathway 
activation. Stimulation of the adenylyl cyclase-cyclic AMP (cAMP)-PKA pathway 
by forskolin or cAMP analogues potentiates DA uptake in rat striatal 
synaptosomes (Batchelor and Schenk 1998, Page et al. 2000), however, 
forskolin stimulation inhibits the function of NET expressed in PC12 cells 
(Nakanishi et al. 1995).  Furthermore, acute ethanol treatment has been shown 
to modulate several aspects of the PKA pathway in mouse brain, including PKA-
dependent phosphorylation of trafficking-related proteins (Hoffman and Tabakoff 
1990, Conti et al. 2009). These findings open the possibility of a PKA-stimulated 
protein altering DAT trafficking through its interactions at IL1. 
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Ethanol could also modulate the interaction of microfilaments with the 
transporter.  Dynamic modulation of the cytoskeleton, which is primarily 
composed of actin and microtubules, is critical for proper protein trafficking.  The 
activity of Eps8, a protein that regulates actin dynamics, was found to be 
sensitive to ethanol (Offenhauser et al. 2006).  Acute ethanol treatment induced 
actin reorganization in an Eps8-dependent manner, altering NMDA receptor 
trafficking.   Ethanol has also been shown to disrupt microtubules, altering 
synaptic trafficking in rat brain (Ahluwalia et al. 2000). However, an ethanol-
induced reorganization of the cytoskeleton would likely result in more global 
changes on protein trafficking, which we did not observe. 
DAT, as well as other monoamine transporters, have been shown to traffic 
and function as homo-oligomers (Sorkina et al. 2003, Torres et al. 2003a).  
Recently, studies investigating the relationship between DAT oligomerization and 
pharmacological-regulated trafficking by amphetamine and cocaine have 
suggested the substrates can modify oligomerization (Chen and Reith 2008).  In 
addition to reducing surface DAT levels, amphetamine also reduces DAT-DAT 
interactions.  Blockade of amphetamine-induced endocytosis counteracted the 
reduction of oligomerization by the drug.  Interestingly, cocaine, which increases 
DAT surface expression, increased DAT oligomerization.  These important 
findings are the first to show a pharmacological regulation of oligomerization and 
the potential linkage to transporter trafficking.  It would be interesting to 
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investigate whether ethanol-induced regulation of endosomal recycling is 
associated with post-translational changes in oligomerization. 
Recent investigations of the involvement of cell surface interfaces of TM2-IL1 
in oligomerization have ruled out the region in DAT-DAT interactions, but suggest 
a role in DA bindings (Sen et al. 2005).  Our findings with the IGLF mutant DAT 
support these findings.  The multiple mutations of could also just be causing a 
misfolding of the protein, rendering the transporter dysfunctional.  However, IGLF 
DAT traffics to the cell surface similarly to WT DAT.  While these results force us 
to reject our hypothesis that the IL1 is required for constitutive trafficking, it would 
be informative to investigate the role of the region in conformational changes 
required for substrate binding.   
6.3 Implications of Ethanol Action on DAT 
Ethanol-mediated enhancement of DAT function likely reflects a 
compensatory mechanism to counter-balance elevated synaptic DA 
concentrations induced by ethanol.  These changes could contribute to an acute 
functional tolerance observed for DA-mediated responses (Fitzgerald and Nestler 
1995). The ethanol-enhanced function and alteration of endosomal recycling of 
DAT could, in particular, negatively impact individuals with abnormal transporter 
levels.  For example, studies have suggested ethanol-modulated DAT levels 
could contribute to the severity of acute withdrawal symptoms. A recent study 
suggested that alcoholics undergoing acute withdrawal actually have elevated 
levels of the transporters, contributing to the severity of the withdrawal symptoms 
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(Cosgrove et al. 2009).  The elevated transporter levels could lead to a decrease 
DA tone, and a greater vulnerability to alcohol dependence.  Acute ethanol 
exposure in these patients could further enhance surface DAT levels, leading to 
an acute tolerance effect, and a possible increase in drinking.  
The findings from the studies presented here describe ethanol effects on 
DAT function and specific steps of the transporter trafficking pathway.  Ethanol 
potentiates DAT-mediated DA uptake by altering regulation of the transporter.  
We found ethanol specifically increases the rate of DAT insertion, resulting in a 
redistribution of the transporter onto the cell surface.   These novel findings are 
the first to describe a molecular mechanism of ethanol action on DAT, and 
provide a framework to further understand the action of ethanol on synaptic 
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